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ABSTRACT 
IDENTIFICATION OF TYPE THREE SECRETION SYSTEM EFFECTORS LINKED TO 




University of New Hampshire 
 
Vibrio parahaemolyticus is an emergent human pathogen that is the leading cause of 
seafood-borne bacterial infections in the United States and worldwide. Recently, clinical 
prevalence of V. parahaemolyticus has increased in the United States, especially from the North 
Atlantic Ocean. The majority of clinical isolates of V. parahaemolyticus harbor a hemolysin gene 
(tdh and/or trh) and a Type III Secretion System (T3SS)-containing mobile Vibrio Pathogenicity 
Island (VPaI). The VPaIs are evolutionary related yet distinct. These VPaIs include VPaIα (tdh+), 
VPaIβ (trh+), and a mosaic VPaIγ (tdh+/trh+). Strains harboring VPaIα cause the most infections 
globally, whose major effectors are known. In the United States, in particular from the North 
Atlantic, human infections with V. parahaemolyticus are predominantly caused by strains 
harboring the relatively uncharacterized VPaIγ. There are four major VPaIγ lineages in V. 
parahaemolyticus strains of North Atlantic, identified by the tdh allele they harbor. Strains 
harboring tdh3-VPaIγ are isolated most clinically, though strains harboring tdh5-VPaIγ are 
environmentally predominant. Using a dual approach of bioinformatics and bioassays, in this study 
we identify five novel T3SS2 effectors on VPaIγ. We provide evidence that suggests a V. 
parahaemolyticus population-based contribution towards its pathogenicity and environmental 
prevalence. Patterns of recombination in toxin orthologs from tdh3-VPaIγ and tdh5-VPaIγ indicate 
  viii 
that the surrounding population is a major contributor to the content of these VPaIs. The divergence 
seen in these orthologs were assessed for contribution towards their effectiveness in pathogenesis 
or environmental fitness. Our predatory grazing assay suggests that one effector may have evolved 
for survival against eukaryotic predators in the environment. Utilizing bioassays to assess toxicity 
and virulence, we found evidence that four of the VPaIγ orthologs likely contribute to the tdh3-
VPaIγ clinical prevalence. This work lays the foundation for understanding VPaIγ effector fitness 
benefits in relation to their environment and population.   
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CHAPTER I: INTRODUCTION 
Vibrio parahaemolyticus  
Vibrio parahaemolyticus is a gram-negative, halophilic bacterium found in brackish water 
throughout the world. V. parahaemolyticus usually exists in a free-swimming state throughout the 
water column in marine, estuarine, and coastal environments, but it also attaches to animate and 
inert surfaces underwater such as suspended solids, sediments, shellfish, phytoplankton and 
zooplankton, fish, and crustaceans 1–5. V. parahaemolyticus is an emergent human pathogen and 
is the leading seafood-borne bacterial pathogen in the United States and worldwide. Food 
poisoning caused by V. parahaemolyticus is generally caused by consuming raw, mishandled, or 
undercooked seafood, including crab, shrimp, shellfish, lobster, fish, and oysters 6,7. Due to their 
filter-feeding mechanisms, shellfish, especially oysters, can concentrate bacteria, including V. 
parahaemolyticus, up to 100-fold higher than the surrounding water 6,8–11. 
 
 Pathogenic Vibrio spp. and their epidemiology 
The genus Vibrio, collectively called Vibrios, belong to the Gammaproteobacteria class of 
bacteria and are members of the Vibrionaceae family 4. They are ubiquitous in aquatic 
environments, and though mostly harmless, some species, or more accurately, some strains of these 
species, cause disease in humans and other animals 4. Vibriosis is a human illness caused by 
Vibrios that do not harbor the cholera toxin. Many bacteria of the Vibrio genus can cause vibriosis 
including most notably Vibrio vulnificus, Vibrio alginolyticus and V. parahaemolyticus 4,8,12–14, 
with the latter three species contributing to the highest amount of human illnesses in the United 
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States 15. Historically, Vibrio cholerae is the most well-known pathogenic Vibrio species since it 
is the causal agent of the disease cholera 16,17. Cholera is associated with contaminated water and 
poor sanitization, causes severe diarrhea and dehydration, and has caused seven pandemics since 
1817 4.  The Centers for Disease Control and Prevention (CDC) monitors V. cholerae infections 
separately from other vibriosis cases due to it high infection rate and death toll 16,17. 
V. parahaemolyticus is estimated to cause 45,000 of the 80,000 vibriosis illnesses each year in 
the United States,15 and is the leading cause of seafood-borne bacterial infections in the United 
States and worldwide 15,18,19. Infection with V. parahaemolyticus can take on three forms: 
gastroenteritis, wound infections, and, rarely, lethal septicemia 18. Wound infections occur through 
the exposure of open wounds to seawater containing V. parahaemolyticus and are most common 
among fishermen followed by those partaking in recreational aquatic activities 6,8,20–22. These 
wound infections can lead to life-threatening septicemia to immunocompromised individuals 6,23 
and require hospitalization and in rare cases can lead to death 2,8,18,24 or necrotizing fasciitis 
resulting in widespread tissue damage 20,21,25.  
The most common form of V. parahaemolyticus infection is gastroenteritis, caused by 
consumption of raw, undercooked, or mishandled seafood that is contaminated with pathogenic 
strains 1,6,7,9,10,20,22. V. parahaemolyticus-induced gastroenteritis is typically mild and self-limiting, 
lasting for 2–10 days 6,7. Symptoms include acute dysentery, abdominal pain, watery diarrhea, 
nausea, vomiting, fever, and chills 6,7,26–28. Pathological changes can vary from mild destruction of 
the jejunum and ileum, and gastric inflammation, to severe cases including internal organ damage 
(liver, spleen, lung congestion, etc.) 6. In rare cases, septicemia can result if V. parahaemolyticus 
crosses the intestinal epithelium 25. Due to the self-limiting nature of gastroenteritis, infection with 
V. parahaemolyticus is often under-reported and most commonly treated at home with oral 
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rehydration 10,18. If reported, antibiotics may be prescribed 6. There have been very few studies on 
non-human V. parahaemolyticus infections. Recent studies reported the damage to the shrimp 
aquaculture industry from V. parahaemolyticus causing Acute Hepatopancreatic Necrosis Disease 
(AHPND), also known as Early Mortality Syndrome (EMS), in penaeid shrimp 29–31.  
 
Human infection with V. parahaemolyticus 
V. parahaemolyticus is ubiquitous worldwide in many diverse populations, but only a 
minority of members within these populations can infect and cause disease 3,19,32–35. V. 
parahaemolyticus infections typically occur seasonally during summer months (from June to 
October in the northern hemisphere) 6 when surface water is warmest, facilitating total V. 
parahaemolyticus populations to rise, including pathogen populations 36. However, V. 
parahaemolyticus infections still occur in cooler water and where there is a low abundance of V. 
parahaemolyticus 19,37,38. Recurrent infections and outbreaks consistently occur in regions where 
surface water remains cool throughout the year, in particular, the Pacific Northwest 22,35,39–41. V. 
parahaemolyticus infections occur worldwide, predominantly in countries with high levels of 
seafood consumption 1. 
 
Infections of V. parahaemolyticus in New England 
Vibriosis cases in the United States have increased 120% from 1996 to 2014 (most current 
data available from CDC as of May 24, 2020 43), with V. parahaemolyticus responsible for 60-
75% of cases 42,43. This increase in reported cases also coincided with a drastic shift in regional 
occurrence. Warmer regions, such as the Gulf of Mexico, shifted from 48% of vibriosis infections 
to 36% 42. Interestingly, the cooler Northeast Atlantic coast region increased in vibriosis infections 
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from 3% in 1996 to 22% of vibriosis infections in 2014 42. Until recently, there was a long-held 
belief based on the rare occurrence of illnesses, corroborated by low environmental abundance of 
hemolysin-harboring members in the environment, that the environmental conditions of the 
Northeastern US did not sustain pathogenic populations of V. parahaemolyticus 33,44. Except for a 
large multi-state outbreak in 1998 from a non-indigenous strain of V. parahaemolyticus originating 
from Southeast Asia in oysters harvested from Long Island Sound, V. parahaemolyticus has caused 
few infections associated with shellfish harvested from the cooler waters of the Northeastern US 
22,26,45–47. However, infections associated with Atlantic shellfish suddenly increased. This 
coincided with warmer than usual ocean temperatures in the region, known to correlate with higher 
densities of V. parahaemolyticus in the water column, and invasion of the Pacific Northwest 
endemic pathogenic strain Sequence Type (ST) 36 8,22,48,49. During this transitional period two 
outbreaks occurred, one in New York in 2012, and the second in New York, Connecticut and 
Massachusetts in 2013 49. Over the past decade, infection rates have continued to rise in the United 
States despite the implementation of control measures, with the Northeast included. The cause of 
this rise is unknown, but one hypothesis attributes this rise to the changing climate on pathogen 
abundance and distribution 50.  
 
Current molecular detection of pathogenic V. parahaemolyticus 
Environmental surveillance/enumeration based on the conditionally adopted FDA BAM 51 for 
V. parahaemolyticus includes quantifying the overall abundance of V. parahaemolyticus using the 
thermolabile hemolysin (tlh) gene present in all strains, as well as the presence of the two 
hemolysin genes tdh and trh, discussed further below, to quantify the number of “pathogenic” V. 
parahaemolyticus. This “pathogenic” V. parahaemolyticus detection method does not provide an 
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accurate measure of the number of pathogenic V. parahaemolyticus nor the degree of pathogenicity 
since 1) not all pathogenic V. parahaemolyticus harbor either tdh and/or trh, 2) not all V. 
parahaemolyticus that harbor these hemolysins are pathogenic, and 3) V. parahaemolyticus 
confers varying degrees of virulence despite the same tdh/trh profile, as inferred by clinical 
prevalence 11,52–54. There is a significant gap in accurate detection of pathogenic strains, and it is 
important to study V. parahaemolyticus populations to develop better detection tools for accurate 
surveillance of the most important pathogenic lineages.  
 
Bacterial Evolution  
Bacteria can adapt to their environment under natural selection through the process of genome 
evolution. This process of changing the content and organization of the bacterial genetic 
information can occur through four general mechanisms: point mutations and gene conversions, 
rearrangements (e.g., inversion or translocation), deletions of DNA, and insertions of foreign DNA 
[e.g., plasmid integration, horizontal gene transfer (HGT), and transposition] 55,56. Gene loss and 
recombination of acquired genes are primary forces by which bacteria adapt to new environments, 
and these are critical forces on the evolution of microbial pathogens 32,55,57–62. Bacteria can acquire 
accessory DNA such as plasmids, bacteriophages, transposons, integrative and conjugative 
elements (ICEs), and genomic islands (GEIs), through the process of HGT 56. HGT is the transfer 
of genetic material from one organism to another non-decedent organism 63. They can also acquire 
homologous DNA harboring unique nucleotide variation by HGT, which can recombine with and 
replace shared genetic content. These acquisitions can provide a fitness advantage beneficial to 
bacteria under certain conditions such as adaptation to changing environmental conditions, 
enhancing virulence, or immune evasion 32,34,56,57,64–66. 
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For HGT to occur efficiently, many bacteria can utilize conjugation machinery to either donate 
or receive DNA directly from other bacteria or receive novel DNA by phage transduction. Vibrio 
spp. have a rare mechanism, termed natural transformation, that enables them to uptake DNA from 
their surrounding environment instead of direct transfer from other bacteria or phage 67–69. When 
grown in the presence of chitin-based substrates, such as those abundant in marine environments, 
Vibrio spp. turn on machinery to take up DNA from their environment 11,34. Natural transformation 
occurs in environmental and pathogenic bacteria, including Acinetobacter spp., Bacillus subtilis, 
Streptococcus pneumoniae, Neisseria gonorrhoeae, Pseudomonas stutzeri, Ralstonia 
solanacearum, and Haemophilus influenzae 56. 
  
Identification of potential virulence determinants of pathogenic V. parahaemolyticus 
Tdh/Trh 
Identification of the virulence effectors important in human gastrointestinal infection of V. 
parahaemolyticus has been an active area of research for years 8,9,70. Initially, many researchers 
believed that the hemolysins, the thermostable direct hemolysin (Tdh), and thermostable related 
hemolysin (Trh), were indicators for the virulence potential of V. parahaemolyticus since most 
enteropathogenic V. parahaemolyticus harbored one or both of those genes, but these genes are 
not essential for human disease 6,8,71–78. 
In 1995 during the initial spread of the pandemic strain of V. parahaemolyticus, pathogenic 
strains were identified by ß-hemolysis on specialized Wagatsuma Blood Agar known as Kanagawa 
Phenomenon (KP) 73. At that time, 95% clinical isolates of V. parahaemolyticus were KP+ (ß-
hemolytic), while 98–99% of the environmental samples were KP- (non-hemolytic) 1,6,75,79,80. This 
KP+ hemolysis is caused by the hemolysin Tdh 6,7,24,72,81,82.  
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In addition to hemolysis, Tdh can also induce cytotoxicity, cardiotoxicity, and enterotoxicity 
7,82. Tdh is termed thermostable direct hemolysin due to its stability at 100°C 7,83. Tdh is a pore-
forming protein that alters ion flux in human cells, causing cytotoxicity. Tdh works in three 
primary steps, it 1) binds to erythrocyte membrane or host cells 2) forms a ~2nm diameter 
transmembrane pore which 3) disrupts the ion flux of Ca2+ and Cl− across the cell membrane, 
increasing the osmotic pressure of the cell exceeding the upper limit for the cell beyond self-
regulation, resulting in cell expansion and death 6,7. So far, there are seven distinct tdh alleles which 
share a nucleotide sequence identity >96.7% 11,82,83.  
Initially during the spread of pathogenic V. parahaemolyticus worldwide, the Wagatsuma 
agar was a good screen for diarrhea-inducing V. parahaemolyticus during the original outbreak of 
the pandemic strain, but then more KP- V. parahaemolyticus caused human sickness. The majority 
of these KP- clinical isolates encode Trh 84–87. Trh is related to Tdh and plays a similar role as Tdh 
in tissue pathoglogy 1,88. Trh is a pore-forming hemolysin and causes similar levels of hemolysis 
as Tdh in vitro 6. It can form hemolytic zones on usual blood agar plates, but not on Wagatsuma’s 
medium, and thus was used to identify KP- strains 83. Wagatsuma’s medium was specially 
formulated to produce distinctive ß-hemolysis in tdh-harboring V. parahaemolyticus  due to the 
specificity of erythrocyte source, pH, salt content, and carbohydrate content 89,90. Two trh alleles 
have been described so far in various Vibrio species 75. 
 
Flaws of tdh/trh as markers of virulence 
Unfortunately, the use of tdh and trh as pathogen screening markers had major flaws. KP was 
only effective in identifying strains harboring tdh, and some clinical isolates did not contain either 
of tdh or trh 8,19,91,92. Also, deletion of these markers does not ameliorate disease in an animal 
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model, and environmentally, a high proportion of tdh and/or trh does not correlate with an increase 
of outbreaks 20,72,87,93.  This is partly due to the fact that many other species of marine bacteria of 
unknown virulence potential also harbor homologous genes 94–96. This suggests that further 
research is needed in identifying virulence factors important in V. parahaemolyticus pathogenicity 
in humans 20,81,97,98.  
 
Urease 
V. parahaemolyticus does not typically produce urease, but some V. parahaemolyticus strains 
carry a ure cluster that enables the production of the enzyme 85,99. Urease is an enzyme that breaks 
down urea into ammonium carbonate. It is produced by many bacteria, fungi, plants, and some 
vertebrates 99. Pathogenic bacteria such as certain strains of Staphylococcus spp., Helicobacter 
spp., and Mycobacterium spp. typically encode urease 99. Bacterial ureases are involved in the 
formation of ammonia during the process of infection, which reduces the acidity of the local 
environment, beneficial for bacterial survival 85,99. Urease also contributes to damage of host 
epithelial cells by activating host monocytes and neutrophils to secrete inflammatory cytokines 
85,99. Urease activity may aid in the colonization of host tissue by bacteria by inhibiting the 
biosynthesis of mucus and cause intestinal mucus to disassemble at the mucosal surface, allowing 
for better access of invading bacteria to the epithelial cells 100–103. Though urease is not essential 
for V. parahaemolyticus infection, it is suggested that it contributes to increased survival of V. 
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Vibrio Pathogenicity Islands 
Pathogenicity Islands – General 
Pathogenicity Islands (PaIs) are a type of genomic island (GI) found on the chromosomes of 
many bacteria 104. PaIs are characteristically large chromosomal regions (10 to 200 kb) inserted 
near tRNA genes and typically harbor functional mobility elements (i.e., direct repeats, integrases, 
transposases, insertion sequences), and differ in base composition from the core genome. 
Importantly, they contain virulence genes and are present in pathogens but absent in benign 
relatives 55. PaIs typically have a mosaic structure due to their numerous acquisitions and 
adaptations 55. Many bacterial pathogens, both gram-negative and gram-positive, have PaIs, 
including prominent human pathogens such as V. cholerae, V. parahaemolyticus, Helicobacter 
pylori, Escherichia coli, Salmonella spp., Shigella spp., Pseudomonas syringae, Listeria spp., 
Staphylococcus aureus, Streptococcus spp., Enterococcus faecalis and Clostridium difficile 104. 
 
VPaI 1-7 
The first fully sequenced V. parahaemolyticus genome was completed in 2003 from the 
pandemic clonal complex strain  RIMD2210633 105. V. parahaemolyticus contains two 
chromosomes. The pandemic strain genome contained seven Vibrio Pathogenicity Islands (VPaIs), 
with VPaI-1, -4, -5 and -6 exclusive to the pandemic strain 105,106. This lineage of V. 
parahaemolyticus gained its human pathogenicity from these VPaIs from unrelated lineages 
34,65,98,105–109. Espejo et al. (2017) reviewed the plausible origins for each VPaI and indicates that 
the O3:K6 non-pathogenic founder strain acquired a toxRS and at least seven novel genomic 
islands 110. All seven VPaIs contain the typical characteristics of pathogenicity islands as defined 
above, such as large size (all were 10-81kb), flanked by direct repeats, G+C content lower than 
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the rest of the genome (except VPaI-2), and flanked by integrases or transposases for mobility. 
VPaI-1-4 were inserted adjacent to tRNA genes 106.  
 
VPaIs known to confer virulence 
 Despite the numerous VPaIs identified from the pandemic clones, almost all clinical V. 
parahaemolyticus isolates contain either one or both hemolysins tdh and trh alongside a Type 
Three Secretion System (T3SS) locus on one of three evolutionarily distinct but related VPaI: 
VPaIα, VPaIß, and VPaIγ 75,98,105,106. Until recently, researchers named each VPaI based on the 
strain that harbored them. VPaIα (tdh+) was previously reported as Vp-PAIRIMD2210633 98/Vp-PAI 
105/VPaI-7 106/tdhVPA 65, whereas VPaIß (trh+) was previously reported as Vp-PAITH3996 
98/trhVPA 65,109. Xu et al. designed a non-strain specific naming system for these islands based on 
the previously designated T3SS they harbored 107. The T3SS2 on VPaIα is evolutionarily divergent 
from the T3SS2 on VPaIß/γ; thus these secretion systems are termed T3SS2α on VPaIα, and 
T3SS2ß on VPaIß 98,107.  VPaIγ contains genetic elements from both VPaIα and VPaIß 107, thus 
due to this hybrid nature was termed “VPaIγ” 65,98,107,109 . A gene map of all three VPaI from Xu 
et al. (2017) is shown in Figure 1.1 107.  
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Figure 1.1: Comparison of gene content and conservation in a typical VPaIα, VPaIβ, and 
VPaIγ. VPaIα was derived from ST3 strain RIMD2210633, VPaIß was derived from ST631 clade 
II isolate MAVP-Q, and VPaIγ was derived from ST631 clade I isolate MAVP-R. ORFs are 
depicted in defined colors, and similarities (≥75%) among ORFs are illustrated in gray blocks. 
Figure from Xu et al. 107 
 
VPaIα, first described in strain RIMD2210633 as VPaI-7, is currently the most extensively 
studied VPaI as it is the VPaI harbored by the pandemic clonal complex of V. parahaemolyticus, 
which causes the majority of infections by V. parahaemolyticus globally 105. VPaIα, as described 
in strain RIMD2210633 (NC_004605 region between VPA1312 and VPA1395), is 81-kb [83 open 
reading frames (ORFs)] and is located on chromosome 2 in RIMD2210633 110. Notably, it contains 
two copies of tdh [tdh1 and tdh2 alleles (tdhS/A respectively) 65] 75,78,111, cytotoxic necrotizing 
factor, an exoenzyme T gene, five transposase genes, and T3SS2α apparatus as well as several 
T3SS secreted toxins 107.  
VPaIß is evolutionarily divergent from VPaIα, with limited shared genetic content 65. VPaIß 
from ST631 clade I strain MAVP-R (MF066647.2) is 96-kb and contains 88 ORFs 65,107 with ~78 
ORFs unique to VPaIß 107 when compared to VPaIα from strain RIMD2210633. VPaIß is located 
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on either chromosome of V. parahaemolyticus dependent on strain 65. VPaIß contains a T3SS2ß, 
which is related to the T3SS in non-O1, non-O139 strains of V. cholerae 98, and harbors one copy 
of trh 98. The VPaIß (from strain MAVP-R) contains other interesting gene content including an 
integrase, transposases, a urease gene cluster, and a peptide/nickel transportation system 65,98.  
By 1990, isolates of V. parahaemolyticus harboring a VPaI that contained both tdh and trh 
caused gastroenteritis 73. Bioinformatics analysis of quality assemblies identified that all strains 
harboring tdh and trh concurrently, harbor these together in VPaIγ 107. VPaIγ is 102-113-kb (~105-
114 ORFs) and is located on chromosome 2 in sequenced genomes. Analysis of this island 
indicated that the gene content is a hybrid of VPaIα and VPaIß 107. The 5’ end of the island contains 
a mix of genes from both VPaIα and VPaIß, including a tdh gene homologous to that from VPaIα 
107. Interestingly, this tdh gene, though apparently from VPaIα, is flanked by gene content from 
VPaIß 107. The core of the island is orthologous in content and syntenous with VPaIß, but 3’ end 
of the island is highly conserved with that of VPaIα 97,107.  
 
Secretion Systems and their Effectors 
Secretion Systems 
Bacteria have developed numerous mechanisms to increase their environmental fitness or 
pathogenic success. The utilization of a protein secretion system is a method commonly used 
among bacterial pathogens. Bacterial secretion systems are highly controlled and specific 
machinery that transfer multiple bacterial encoded proteins across phospholipid membranes 112. 
As reviewed in Green and Mecsas (2016), bacterial pathogens often use these systems to 
successfully invade hosts, damage host tissue, and evade host immune defenses 113.  
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To date, there are seven bacterial secretion systems. The first six secretion systems are in 
gram-negative bacteria and the seventh is found in only a few species of Mycobacteria and 
Corynebacteria. The six gram-negative secretion systems are depicted in Figure 1.2 as originally 
published by Gunasinghe (2017) 114. Type I Secretion Systems (T1SS) resemble ATP-binding 
cassette (ABC) transporters, and they transport their substrates across both inner and outer 
bacterial membranes 113,115. Type II Secretion Systems (T2SS) form a channel in the outer bacterial 
membrane, and transport folded proteins from the periplasm of bacteria, across the outer 
membrane, into the extracellular environment 113. Type III Secretion Systems (T3SS) are discussed 
below. Type IV Secretion Systems (T4SS) are related to bacterial DNA conjugation systems. They 
can transport single proteins, protein-protein, and DNA-protein complexes across both its own 
bacterial inner and outer membranes, but also other bacterial and eukaryotic membranes allowing 
for direct injection of the substrate into a recipient cell’s cytosol 113,116. Type V Secretion Systems 
(T5SS) are unique systems of autotransporters that allow secretion of proteins or groups of proteins 
across the outer membrane of gram-negative bacteria 113,117. Type VI Secretion Systems (T6SS) 
are large structures that, like T3SSs and T4SSs, translocate proteins directly from their cytosol into 
the cytosol of other cells in a contact-dependent manner, though T6SS can translocate proteins into 
both bacterial and eukaryotic cells 113,118. Type VII Secretion Systems (T7SS) are the secretion 
systems specialized for transport of proteins across the heavily lipidated cell wall layer found in 
gram-positive organisms such as Mycobacteria and Corynebacteria 113. 
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Figure 1.2. Architecture of the major protein secretion systems found in gram-negative 
bacteria. Figure from Gunasinghe (2017) 114. Of the six major gram-negative protein secretion 
systems, five span the inner and outer membranes and the periplasm. These nanomachines are 
thereby trapped in the peptidoglycan layer. The T1SS, T3SS, T4SS, and T6SS collect substrate 
proteins directly from the cytoplasm for secretion across both membranes, while the T2SS collects 
substrate proteins from the periplasm with their delivery there being via the Sec translocon (shown) 
or Tat transport system (not shown).  
 
T3SS 
Discovered in the 1990s 119, the T3SS is a bacterial needle-like apparatus that can detect 
eukaryotic cells, and inject bacterial protein effectors directly into the plasma membrane and 
cytoplasm of the eukaryotic cell 1,20,120. Once in the eukaryotic cell, these bacterial effectors can 
hijack host cell signaling and can manipulate host cell functions to benefit the bacteria 20,119,120. 
This apparatus, termed the injectisome, is evolutionary related to the components of the bacterial 
flagellum that are involved in flagellar structure assembly 1,119,121. 
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Though also essential to some symbionts, T3SSs are typically found in gram-negative 
animal, plant, insect and amoeba pathogens, and tend to contribute to their virulence 119. Some 
important human pathogens that use T3SSs for their virulence include Salmonella enterica 
serovars, Shigella spp., Yersinia spp., Chlamydia spp., Pseudomonas spp., Vibrio spp., Bordetella 
spp., and pathogenic strains of E. coli 112,119. 
A total of 20-30 proteins make up the structure of the injectisome, forming three primary 
sections: the secretion apparatus, transposon pore, and needle 1,20. The secretion apparatus 
traverses both the inner and outer bacterial membranes 1,20. The transposon pore is composed of 
secreted proteins called translocators, which form a hole crossing the target eukaryotic membrane 
1,20. The  approximately 60-nm-long needle is polymerized and extended into extracellular space 
to connect the secretion apparatus and transposon pore 1,20,119. Genes for the injectisome and its 
translocators are commonly encoded within a single gene cluster located on a mobile genetic 
element such as a plasmid or pathogenicity island and thus can spread between bacteria through 
the process of HGT 119. 
 
T3SS Effectors 
T3SSs typically deliver multiple effector proteins in a coordinated fashion to modulate a variety 
of complex cellular processes enabling the bacterium to colonize its host 20,112. T3SS effectors 
typically function through some of the following themes: mimicry of host cell proteins, covalent 
modifications of host cell proteins (e.g. phosphorylation, acetylation, and AMPylation) to 
transiently alter the activity of the host cellular targets, work in concert with other effector proteins, 
and work under precise temporal regulation/localization 112. T3SS effectors have functional 
redundancy in that they may have different biochemical activity, but target a similar cellular 
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process for a similar net result 112. Homologous effectors can be encoded by very dissimilar 
pathogens, but each homolog may produce a different effect in their recipient hosts 112. 
Importantly, T3SS effectors are often encoded outside of the genetic block encoding the 
injectisome apparatus, allowing for greater nucleotide variation and recombination among 
effectors while retaining a functional secretion apparatus 119. 
 
V. parahaemolyticus T3SSs and Virulence Effectors 
V. parahaemolyticus T3SS 
All V. parahaemolyticus have an ancestral T3SS (T3SS1). Some pathogenic V. 
parahaemolyticus also have a second horizontally acquired T3SS harbored on VPaIα/ß/γ (T3SS2α 
or T3SS2ß), which makes them enterotoxic 9,84,98,105,119,122. T3SS1 is located on Chromosome 1 in 
all V. parahaemolyticus 35. T3SS1 effectors have a cytotoxic effect in cell culture, but they are not 
an important component of enterotoxicity 8,9,123,124. T3SS1 has four main effectors, VopQ, VopS, 
VopR, and VPA0450 (Table 1.1,  adapted from Wang et al. 2015) 6 that initiate a series of events 
in tissue culture that cause autophagy, membrane blebbing, cell rounding, and cell lysis 1,123. 
T3SS1 effectors are thought to be important for systemic V. parahaemolyticus infections and may 
determine the final outcome of disease 125. 
T3SS2 is an accessory system on VPaIα/ß/γ, primarily in pathogenic strains of V. 
parahaemolyticus 1,23,35,70,105,122. The T3SS2 found in V. parahaemolyticus has close homology to 
the T3SS Hrp1 system in Pseudomonas syringae 1. Effectors of T3SS2α have been extensively 
studied and are discussed in the following section. Some of the effectors with no proven role in 
human disease are also secreted by T3SS2ß, but there is little homology between the primary 
T3SS2α effectors VopV and VopZ with those similar regions found on VPaIß/γ 107. During 
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gastrointestinal infections, the effectors from both T3SS2α/ß impair epithelial cell function and 
structure resulting in damage to the intestinal lining, inflammation, and diarrhea 9. 
 
T3SS2 effectors and Gastroenteritis Pathogenesis 
The human gut mucosa makes up the primary barrier to the underlying tissues and organs 
of the human body. The first layer of the gut mucosa are epithelial cells termed enterocytes, with 
occasional specialized epithelial cells. One mechanism of gut pathogen proliferation and survival 
is to disrupt this barrier to gain access to the tissues underneath 126.  
After consumption, when V. parahaemolyticus makes it to the intestinal tract, it first must 
attach to the enterocytes. A tight attachment to enterocytes is necessary for the bacterial T3SS 
needle to form a channel and pump effectors into the host cell. Throughout the length of the 
gastrointestinal tract, there is variation in mucus density, commensal flora composition and a wide 
diversity of cell types 20. Due to the highly dynamic environment of the gastrointestinal tract, V. 
parahaemolyticus has developed multiple adhesion mechanisms to allow for efficient attachment 
to host cells throughout the intestine 20,125. This attachment is modulated by the adhesion 
molecules: Mannose Sensitive Hemagglutinin (MSHA) Type IV Pilus and Multivalent Adhesion 
Molecule 7 (MAM7), which bind to the fibronectin and phosphatidic acid on the enterocyte  6,20,127–
129. Though more studies are needed, it is also suggested that Cell-Associated Hemagglutinin 
(cHA), GlcNAc Binding Protein A (GbpA), and Capsular Polysaccharide (CPS) also have an effect 
on adhesion to enterocytes 20,125,130–133.  
After attachment, the T3SS2’s translocators form a pore in the enterocyte membrane 
allowing the T3SS to begin pumping virulence effectors into the enterocyte. The T3SS 
translocation pores forms preferentially in lipid raft microdomains that are rich in cholesterol and 
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glycosphingolipids in the enterocyte membrane. The cholesterol in these lipid rafts binds the TTSS 
translocator proteins so they can assemble as pore 134. After assembly of the translocon pore, the 
T3SS can pump virulence effectors into the enterocyte.  
Characteristic pathological changes during V. parahaemolyticus infection include 
disruption of the intestinal epithelium, modulation of epithelial cell signaling, epithelial cell death, 
and intense inflammation. These pathological changes are primarily attributed to V. 
parahaemolyticus TTSS2 effectors 20. V. parahaemolyticus’s T3SS2 and its effectors have been 
extensively characterized in VPaIα (Table 1.1) 6. The eight characterized VPaIα effectors include 
VopA/P, VopC, VopL, VopO, VopT, VopV, VopZ, and VPA1380.  VopV and VopZ are the two 
primary effectors necessary for successful V. parahaemolyticus infection. VopA, VopC, and VopT 
directly alter the activity of eukaryotic cell signaling proteins by post-translation modification 125. 
 
V. parahaemolyticus Gastroenteritis Pathogenesis - Epithelial disruption (VopV, VopL, 
VopC, VopO) 
One of the common pathologies of bacterial gastric infections includes disruption of the 
intestinal epithelium 135. One function of the gastrointestinal epithelium is to form a selectively 
permeable barrier. This barrier controls the passage of nutrients, water, and ions into the tissue 
below 20,136. By disrupting this primary barrier, gastric pathogens can increase non-selective 
intestinal permeability, modulate ion and fluid efflux and allow bacteria access to deeper tissues 
and interfere with host immune responses 20.  This access to deeper tissues is often associated with 
severe clinical symptoms 126. During infection, V. parahaemolyticus induces significant epithelial 
damage (Figure 1.3), including epithelial cell detachment and disruption of the villus structure, 
triggering a substantial inflammatory response that contrasts with V. cholerae which does not 
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cause inflammatory gastroenteritis  125,135,137. This epithelial damage occurs both on the large scale 
of villus architecture, but also the small scale of effacement and elongation of microvilli 135,138,139. 
V. parahaemolyticus colonizes throughout the small intestine (duodenal) and large intestine 
(rectal) tissues and is highest in the distal small intestine 125. During infection, V. parahaemolyticus 
exhibits a distinct colonization pattern of discrete microcolonies rather than even distribution 
across the entire epithelial surface 138.  
 
Figure 1.3. Schematic of the kinetics of V. parahaemolyticus-induced damage to the intestinal 
epithelial surface. The purple rods represent V. parahaemolyticus. Figure from Ritchie et al. 2012 
138. Following initial attachment, V. parahaemolyticus induces erosion of microvilli and depletion 
of cytoplasmic contents resulting in the formation of bacterial clusters located just below the level 
of the surrounding epithelium. Continued depletion of epithelial cell contents either by cytoplasmic 
‘blebbing,’ whole-cell extrusion and microvilli elongation around the edge of the cluster, leaves 
V. parahaemolyticus clusters situated within deeper cavities in the epithelium. Eventually, this 
leads to the disintegration of normal villus structure and the generation of large amounts of luminal 
debris. These pathological changes appear to be attributed to T3SS2 as a similar pathology was 
observed in rabbits infected with mutants lacking TDH or T3SS1.  
 
The nucleation of actin, actin-bundling, and formation of stress fibers/filopodia/actin 
ruffles serve both a structural and signaling purpose of the host cells. When pathogens disrupt the 
normal branched architecture of the actin cytoskeleton structure of host epithelial cells, these cells 
lose their shape and tight junctions to surrounding cells, which facilitates bacterial dissemination 
140. The proper response to infection and damage cannot be induced when the normal cellular 
signaling network is disrupted 140. During V. parahaemolyticus infection, epithelial disruption is 
primarily caused by the T3SS effectors VopV, VopL/F, VopC, and VopO which target the actin 
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cytoskeleton 125,141,142. VopV binds and bundles the actin in host cells, VopL nucleates actin which 
forms stress fibers thus altering host cell shape, VopC activates GTPases that lead to the formation 
of stress fibers, actin ruffles and filipodia, and VopO induces stress fiber formation 125,141–145. 
Interference and reorganization of the actin cytoskeleton affects not only cell structure, but it also 
activates several signal-transduction pathways, including two important for bacterial infection: the 
mitogen-activated protein kinases (MAPK) signaling and NF-kB inflammatory responses 141,146  
Once secreted into enterocytes, via its F-actin binding-domains, VopV binds to actin filaments 
and the actin-cross linking protein filamin 139. Then by bundling the actin, VopV induces the 
rearrangement of the apical epithelial cell membrane, eliminates the actin-filled microvilli brush 
border, and elongates a few microvilli 141. This effacement of the brush border enhances V. 
parahaemolyticus adhesion to the enterocyte 139. It is proposed that the effacement either provides 
an altered surface for adhesion or exposes membrane domains and/or a specific host receptor that 
V. parahaemolyticus does not have access to with an intact brush border 139.  It is currently not 
known how the F-actin-binding activity of VopV affects VopV-dependent inflammation and 
enterotoxicity 141. VopV is considered the primary effector in VPaIα and is responsible for T3SS2-
dependent enterotoxicity, and colonization 139,141. In the rabbit ileal loop model, vopV deletion 
mutant V. parahaemolyticus induces intestinal damage similar to that of no secretion of any T3SS2 
effector and non-infected control, compared to the severe intestinal inflammation (epithelial loss, 
edema, neutrophil infiltration in the lamina propria and submucosal area, loss of goblet cells, and 
bleeding) seen with VopV secretion 141. This suggests that the effacement of the enterocyte brush 
border is a critical step for V. parahaemolyticus infection 139,141. 
VopL, VopC, and VopO also affect the actin cytoskeleton, but these effectors are not required 
for enterotoxicity 141–144,147. The protein domains of VopL mimic a eukaryotic actin-nucleating 
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protein that allows it to remodel the actin network by inducing the formation of unbranched actin 
structures rather than the branched networks 142. This actin nucleation process forms elongated 
stress fibers and alters the cell shape 1,142,148. VopC utilizes a mechanism other than direct contact 
to manipulate the actin cytoskeleton 143,144. VopC activates the small GTPases Rac and CDC42 to 
contribute to stress fibers, actin ruffles, and filipodia formation 143,144,149. Zhang et al., Okada et 
al., and de Souza Santos et al. suggest that VopC and VopL help facilitate the entry of V. 
parahaemolyticus into non-phagocytic host cells 143,144,150. Recently, a germ-free mouse model was 
developed to assess gastrointestinal pathogenesis of V. parahaemolyticus 151. This model enabled 
assessment of gastrointestinal pathogenesis in earlier hours of infection to evaluate initial tissue 
invasion rather than the final result of maximal tissue damage at the end of infection as seen in 
previous models 138,144,151. In this model during the early hours of infection VopC promoted 
epithelial cell invasion and increased gastrointestinal pathogenesis 151. VopO is an effector that has 
been shown to activate the RhoA-ROCK signaling pathway, which induces actin stress fiber 
formation, contributing to the disruption of the host epithelium 145. 
 
V. parahaemolyticus Gastroenteritis Pathogenesis – Cell Death (VopT) 
Another characteristic pathological change during V. parahaemolyticus infection includes 
epithelial cell death. During infection, cell death can be a host defense mechanism, to limit 
infection and colonization by enteric pathogens 126,152. Some enteric pathogens block apoptosis to 
preserve their replication sites, while others such as V. parahaemolyticus, trigger cell death to 
induce breaches in the epithelium to gain access to underlying tissue 126,152. 
VopT shares the ADP-ribosyltransferase domain of Pseudomonas aeruginosa cytotoxins ExoT 
and ExoS, with biological activity more similar to that of ExoS 124. VopT is cytotoxic to cultured 
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intestinal cells but is not enterotoxic 124,141. VopT can modify Ras, which could affect any number 
of the Ras signaling pathways such as the mitogen-activated protein kinases (MAPK) and 
phosphoinositide-3 kinase (PI3K) pathways, which are important in controlling several functions, 
such as cell growth and survival 124,153,154.  
 
V. parahaemolyticus Gastroenteritis Pathogenesis – Inflammation (VopZ, VopA/P) 
Finally, another hallmark of V. parahaemolyticus induced gastroenteritis is severe 
inflammation, which is specifically induced by V. parahaemolyticus, not the host in response to 
the extensive tissue disruption 125. Pathogens trigger inflammation as a mechanism to outcompete 
the commensal microbiota, disrupt tight junctions and impair gut barrier integrity 126,155,156. Some 
pathogens exhibit higher resistance to host mucosal antimicrobial peptides compared to 
commensals; thus inflammation alters the microbiota composition in favor of the pathogen 126,157–
159. Certain pro-inflammatory cytokines produced by host cells, such as Tumor Necrosis Factor-α 
(TNF-α), disrupt the tight junctions between the enterocytes lining the intestinal tract 126,155,156. 
This disruption allows bacteria access to deeper tissues 126,155,156. V. parahaemolyticus induces 
inflammation through recruitment of inflammatory cells, such as PMNs, and induces host cell 
transcription of the pro-inflammatory cytokines TNF-α, Interleukin-1β (IL-1β), Interleukin-6 (IL-
6), and Interleukin-8 (IL-8) 125,135.  
Commonly, the effectors of bacterial pathogens target the host intracellular signal 
transduction cascades 160. Two of the most frequent effector targets are the inflammatory cell-
survival pathways controlled by the MAPK signaling cascade, and the NF-kB signal transduction 
pathway 160. The MAPK signaling cascade is essential for normal operation of the eukaryotic cell 
such as cellular metabolism, growth, and division, as well as inducing inflammation as an 
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antimicrobial defense mechanism 160. The NF-kB signal transduction pathway is an important 
component of innate immunity, with a role in apoptosis, cell survival, and cytokine production 
160,161. Inhibition of these pathways leads to inflammation, distorted epithelial structure, cell death, 
reduced barrier function, and recruitment of PMNs 147. 
The second critical V. parahaemolyticus T3SS2 effector is VopZ. VopZ is a 
multifunctional effector that is essential for V. parahaemolyticus colonization, enterotoxicity, and 
induction of diarrhea 147. VopZ inhibits activation of the kinase TAK1, which is important for the 
activation of the two signaling pathways MAPK and NF-κB 147,162. Previous studies have shown 
that absence of TAK1, and thus non-activation of MAPK and NF-κB signaling pathways, in the 
intestinal epithelium can lead to phenotypes such as inflammation, apoptosis, distorted epithelial 
structure, mislocalization of tight junction proteins, and reduced barrier function 125,147,163. These 
phenotypes are advantageous for invading enteric pathogens, allowing for increased colonization 
and access to deeper tissues 141,146. 
Another inflammation-inducing effector is VopA (also referred to as VopP). VopA 
acetylates MAPK kinases, preventing phosphorylation of the kinase, thus inhibiting the MAPK 
signaling pathways 1,164,165. Despite its role in controlling cytokine production, VopA is not a 
critical effector for infection as there was no obvious reduction in enterotoxicity in rabbit ileal loop 
141. 
 VPA1380 is a T3SS secreted cysteine protease that likely targets a host substrate 166. Its 
role in V. parahaemolyticus infection is not known. When expressed intercellularly VPA1380 is 
toxic to yeast,  but it is not enterotoxic in the rabbit ileal loop model 141,166. 
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Table 1.1: Known V. parahaemolyticus virulence effectors and their biological activity. 
Gene names are orthologs found in strain RIMD2210633 VPaIα (NC_004605 region between 
VPA1312 and VPA1395). “+” = the presence of effector on VPaIα/ß/γ. “-” = the absence of 
effector and predicted effector on VPaIα/ß/γ.  “~” = divergence between orthologs found in 
VPaIß/γ compared to the characterized effector in VPaIα.     
Gene presence 
on VPaI 
Effector Gene Biological Activity Effects on host cells α ß γ 
Toxins             
Tdh tdh Forms pores on cells Cytotoxicity and enterotoxicity + - + 
Trh trh Forms pores on cells Cytotoxicity and enterotoxicity - + + 
Tlh tlh Hemolysin activity Cytotoxicity N/A N/A N/A 
T3SS1 effectors 
  
          
VopQ VPA1680 Forms pores and binds V-
ATPase 
Autophagy, cell lysis, MAPK 
activation, IL-8 secretion 
N/A N/A N/A 
VopS VPA1686 Inhibition of Rho by 
AMPlyation 
Cell rounding, phagocytes 
invasion 
N/A N/A N/A 




N/A N/A N/A 
VopR VPA1683 Binds PIP2 in membrane Promoting refolding of T3SS 
effectors 
N/A N/A N/A 
T3SS2 effectors 
  
          
VopA/P VPA1346 Inhibition of MAPK by 
acetylation of MKK 
Blocking of phosphorylation 
and ATP binding 
+ + + 
VopT VPA1327 Ras ADP-ribosylation Cytotoxicity and yeast growth 
inhibition 
+ - - 
VopL VPA1370 Actin nucleation Stress fiber formation and cell 
shape changing 
+ + + 
VopC VPA1321 Activation of Rac and 
CDC42 by deamination 
Invasion of non-phagocytic 
cells, enterotoxicity 
+ + + 
VopO VPA1329 Activates the RhoA-ROCK 
pathway 
Induces stress fiber formation  + - - 
VopV VPA1357 Actin binding and bundling Enterotoxicity and blunting of 
villi 
+ ~ ~ 
VopZ VPA1336 Inhibition of TAK1 and 




+ ~ ~ 
VPA1380 VPA1380 Cysteine catalysis dependent 
on IP6 
Toxicity in yeast + - - 
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Epidemiology of V. parahaemolyticus 
V. parahaemolyticus discovery 
V. parahaemolyticus was discovered by Tsunesaburo Fujino of the Research Institute of 
Microbial Diseases (RIMD), Osaka University in 1950 in Osaka, Japan after an outbreak of acute 
gastroenteritis from Shirasu in 272 individuals, 20 of whom died 167. In the decades after this event, 
outbreaks continued and V. parahaemolyticus became recognized as the leading cause of seafood-
borne gastroenteritis 168–175. 
 
ST3 (O3:K6) 
Prior to 1995, gastroenteritis caused by sporadic V. parahaemolyticus infection was 
associated with many serotypes 45,176,177. In 1995, an outbreak of V. parahaemolyticus occurred in 
Calcutta (now known as Kolkata), India 2,26,176. This outbreak was caused by a novel strain of V. 
parahaemolyticus with serovar O3:K6 (with numerous serovariants), later determined by Multi-
locus sequence typing (MLST) to be ST3 26,65,178,179. This ST3 strain spread throughout Asia180 178, 
Africa181, Europe182, and North and South America 18,173,178,180,183,184  and so was called the 
pandemic clonal complex of strains 26,110,178. Since then, ST3 strains have caused numerous food-
borne outbreaks in Asian countries, the United States and worldwide 1,110. ST3 strains of V. 
parahaemolyticus have only caused two outbreaks in the United States, one from Texas oysters 
and the other from New York oysters in 1998 26,45,46. Although not prevalent in the United States, 
the pandemic complex of ST3 strains causes the most disease globally 26,45,173,176,178,185–188. The 
T3SS effectors on the VPaIα harbored by the pandemic strain induced the gastroenteritis seen in 
these outbreaks 65,98,105,106. 
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Arrival in the United States 
The first reported V. parahaemolyticus outbreak in the United States was in Maryland in 1971, 
with three outbreaks 189. The illnesses were linked to steamed crabs 189. There was variation in the 
clinical isolates from these outbreaks with multiple serotypes, and both KP+ (VPaIα) and KP- 
isolates (no island/VPaIß/VPaIγ) 189. V. parahaemolyticus has continued to cause sporadic 
infections in the United States 18. Serotypes with O4 were the most dominant in the United States 
45,176,177. In the United States, the most clinically prevalent STs harbor VPaIß and VPaIγ 19,39,40,190. 
 
 Northeast United States 
Historically there was low disease incidence of V. parahaemolyticus infections in the Northeast 
United States. This low prevalence of disease in the Northwest Atlantic was attributed to cooler 
water and unfavorable conditions for pathogen populations to establish compared to warmer 
southern regions like in the Gulf of Mexico 33,52. The rare outbreaks that did occur were driven by 
anomalously warm ocean temperatures, and introduced strains 22,48,50,185. The recent increase in V. 
parahaemolyticus infections in the North Atlantic are attributed to the invasion and establishment 
of Pacific-native lineages, in particular hypervirulent ST36, as well as a trend of warmer than usual 
ocean temperatures allowing more successful movement and establishment of Gulf of Mexico 
(GOM) native V. parahaemolyticus populations 22,26,35,48,191–196. During this time VPaIs were 
donated from the invading lineages to the native New England populations 11,22,197. 
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Figure 1.4. Clinically prevalent Sequence Types (ST) and corresponding pathogenicity island 
content. Adapted from Xu et al. 2017 11. A) The total number of clinical and environmental 
isolates from prevalent V. parahaemolyticus lineages reported in four Northeast US States (ME, 
NH, MA, and CT) from 2010-2016. B) Percentage of pathogenicity island type from prevalent V. 
parahaemolyticus lineages reported in panel A. C) Distribution of VPaI type of all gastric 
infections reported in ME, NH, MA, and CT. 
 
ST36 (O4:K12) and other Pacific lineages 
V. parahaemolyticus ST36 is a long-time resident lineage originating from the Pacific 
Northwest and is the most clinically prevalent lineage of V. parahaemolyticus in the United States 
and Canada 22,39,40,48,107,177,193,198. ST36 was first identified in the Pacific Northwest (PNW) in 1979, 
and until 2006, this PNW resident lineage only contributed to infection on the Northwest US coast 
52,177,180,199. In 1997, ST36 caused the first outbreak linked to US product along the Pacific Coast 
200. Infections from this outbreak caused 207 confirmed cases and one death 200. The outbreak was 
precipitated by unusually warm ocean temperatures 200. ST36 was also a major contributor to 
multiple outbreaks in 2006 in New York, Oregon, and Washington 201. Prior to 2012 members of 
the ST36 clonal complex were introduced into the Atlantic Ocean by an unknown route and 
established robust local populations 22,48. In 2012 members of these populations caused a series of 
outbreaks from Atlantic shellfish originating from New York and Spain 48,49.  
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Pacific-derived ST36 lineage continues to dominate infections in the Northwest Atlantic 107. 
This pattern of invasion of Pacific-native strains into the Atlantic causing outbreaks also included 
pathogenic sequence types ST636 and ST43 39,40. In 2011 and 2013 and in continuing years ST636 
and ST43, respectively, caused infections linked to products from along the Northeast US coast 22. 
ST36, ST43, and ST636 all harbor VPaIγ.  
 
ST631 
In the past decade, a new lineage of pathogenic V. parahaemolyticus emerged in the 
Northwest Atlantic known as ST631. ST631 was first reported in 2007 from a clinical case reported 
in Maryland that was traced to oysters harvested in Florida 198. The second reported clinical case 
arose two years later traced to Prince Edward Island, Canada 40. Since then, ST631 infections have 
increased with 35 confirmed cases reported between 2010 and 2015 in just four Atlantic coastal 
US states 197. With this increase, ST631 has become the second most predominant pathogenic 
lineage in the Northwest Atlantic, after ST36 22,40,197,198. This emergence of ST631 as a major 
endemic pathogen 107 also coincided with a trend in warmer ocean temperatures in the Northwest 
Atlantic and invasion by nonresident pathogen lineages 22,48,50,185. Non-native pathogen lineages 
included several Pacific native lineages (ST36, ST43, and ST636), and long-time residents of the 
Gulf of Mexico (ST34, ST110, and ST308).  
Population analysis of the Northwest Atlantic clinical and environmental isolates indicates 
that two clades diverged from a common ST631 ancestor, each with strains independently 
acquiring VPaIs from the invading nonresident pathogen lineages 11,107. Isolates of ST631 clade I 
harbored either no VPaI or VPaI-ß and were not clinically prevalent 107. Analysis of the ST631 
clade II isolates indicate that it is the clonal clade II that is the major Atlantic endemic pathogenic 
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lineage 11 that dominates Atlantic-derived ST631 infections. ST631 clade II harbors VPaIγ that 
was likely donated by the same population as ST36 during its Atlantic invasion 11,107. 
 
Long-time residents of the Gulf of Mexico and their spread 
 The long-term resident lineages of the Gulf of Mexico (GOM) harbor primarily no island, 
VPaIß, or VPaIγ. Strains harboring VPaIα are isolated occasionally, but have not established a 
population since most tdh+ isolates in the area are also trh+ 53. STs such as ST34, ST110, and ST308 
are native to the GOM that harbor VPaIγ have moved up the coast and are now resident in the 
Northwest Atlantic 22,53,60,190,192. 
GOM native ST34 was first reported in both the GOM and Massachusetts in 1998 107. During 
the past decade, coinciding with a trend in warmer ocean temperatures, ST34, along with other 
members of the Gulf of Mexico V. parahaemolyticus population 53,60,192, has continued its spread 
north and in 2012 it was also recovered in New Hampshire, where it established residency 22. GOM 
strains moving north have also spread their VPaIs via HGT to local populations 11. Analysis of the 
VPaIs, show that during its spread north, ST34 donated its VPaIγ to the local North Atlantic 
resident ST674, transforming it into a pathogen 11. ST34 and ST674 are the most frequently 
recovered pathogen lineages among environmental isolates, but despite harboring a VPaIγ, they 
cause very few infections 107.  
 
Flavors of VPaIγ 
Pathogenic lineages of V. parahaemolyticus harboring VPaIγ are increasingly associated 
with disease in North America 19,22,39,40,52,198. Whereas most Northeast Atlantic V. 
parahaemolyticus pathogens harbor related VPaIγ, there is variation in their clinical prevalence 11. 
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A recent study by Xu et al. indicated that the geographical location and clinical prevalence of 
VPaIγ could align with allelic variation and lineage of the tdh gene 11. There are currently seven 
tdh alleles harbored by VPaIs. tdh1, tdh2, and tdh4 alleles are located on VPaIα, whereas VPaIγ 
contains one of four distinct tdh alleles: tdh3, tdh5,  tdh6, or tdh7 11.  
In the United States, the primary populations of VPaIγ-harboring V. parahaemolyticus are 
either in the Pacific Ocean, the Gulf of Mexico, or the Atlantic Ocean. tdh3 is exclusively harbored 
in Pacific-derived lineages, and V. parahaemolyticus harboring tdh3-VPaIγ are linked to high 
clinical prevalence 11. tdh5 is closely related to tdh3, but is in V. parahaemolyticus lineages from 
the Gulf of Mexico and the Atlantic Ocean 11,22,107,190,198. All lineages harboring tdh5-VPaIγ are of 
low clinical prevalence 11. tdh7 is divergent from the other tdh alleles, and has been isolated in 
both Pacific-derived and Gulf of Mexico-derived lineages 11,39,40,53. tdh6 has been found in lineages 
worldwide 11. V. parahaemolyticus harboring all of these VPaIγ lineages have invaded the US 
Atlantic coast, causing infections, and are spreading the VPaIs to the local V. parahaemolyticus 
residents, transforming them into pathogens 11. Since pathogen lineages harboring tdh3/tdh5/tdh6-
VPaIγ vary so much in clinical and environmental prevalence, this suggests that each VPaIγ could 
have evolved to confer different degrees of virulence 11.  
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RESEARCH OBJECTIVES 
Chapter II: What T3SS effectors does VPaIγ encode? 
V. parahaemolyticus strains harboring VPaIγ cause the majority of infections in the North Atlantic, 
yet the effectors on this island remain unidentified and uncharacterized. The first objective 
(Objective I) is to identify the T3SS effectors that are present on VPaIγ. The approach to address 
this objective was to conduct a bioinformatic prediction of putative effectors VPaIγ based on 
nucleotide sequence similarity and protein domains to know T3SS effectors. The toxicity of the 
predicted proteins in two eukaryotic models, as a proxy for enterotoxicity, was used to characterize 
which toxins are likely most important to human disease. 
 
Chapter III: Which VPaIγ T3SS effector alleles are important for human disease and 
environmental prevalence? 
There are four flavors of VPaIγ in the North Atlantic, reflected in the allelic variation of tdh on the 
island. Each lineage varies in clinical and environmental prevalence, with tdh3-VPaIγ 
predominantly causing infections yet rarely isolated environmentally, and tdh5-VPaIγ with the 
reciprocal relationship. The second objective (Objective II) is to compare the T3SS effectors of 
the local VPaIγ lineages to examine if sequence variation equates with differences in toxicity in 
eukaryotic models of clinical and environmental fitness. 
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Abstract 
Vibrio parahaemolyticus, the leading cause of seafood-borne bacterial infections, recently 
increased in clinical prevalence in the United States, particularly from sources in the northwest 
Atlantic Ocean. Most pathogenic variants of V. parahaemolyticus harbor a mobile Vibrio 
Pathogenicity Island (VPaI) encoding a diagnostic hemolysin gene (tdh and/or trh) and a Type III 
Secretion System (T3SS). Three island types have been characterized and include VPaIα (tdh+), 
VPaIβ (trh+), and a mosaic VPaIγ (tdh+/trh+). Although most infections globally are caused by 
strains harboring VPaIα, for which several major effectors are known, infections in the United 
States are predominantly caused by strains harboring VPaIγ, which is relatively uncharacterized. 
Our goal was to identify effectors in VPaIγ using bioinformatics and bioassays. Analysis predicted 
five putative effectors shared between VPaIβ and VPaIγ but absent in VPaIα. When expressed 
intracellularly, three predicted effectors impaired Saccharomyces cerevisiae growth similarly to 
the known effector VopA, suggesting they are T3SS2 effectors. However, a third predicted effector 
did not impair growth, nor did VopZ, one of the major virulence determinants of VPaIα. Four 
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effectors were cytotoxic to cultured human colon cells, warranting further investigation of their 
role in human gastroenteritis.  
 
Introduction 
Vibrio parahaemolyticus is the leading cause of bacterial-induced seafood poisoning both 
in the United States and worldwide. Infection with V. parahaemolyticus can take on three forms: 
gastroenteritis, wound infections, and, rarely, lethal septicemia, with the most common form as 
gastroenteritis 18. Recent increases in infections in the Northeast US from Atlantic-harvested 
shellfish coincided with warmer than usual ocean temperatures, and the invasion of a lineage of 
the “hypervirulent” Pacific Northwest endemic pathogenic strain called Sequence Type (ST) 36 
8,22,48,49. Increasing illnesses have also been caused by an endemic pathogenic lineage, ST631 clade 
II, first reported in the North Atlantic in 2007 and which acquired a VPaIγ from the ST36-
containing population 11,107. Currently, ST36 causes the vast majority of infections in the North 
Atlantic, followed by ST631 clade II 11,107.   
The Type Three Secretion System (T3SS) is a needle-like apparatus that can inject effector 
proteins directly through the plasma membrane and into the cytoplasm of a eukaryotic cell 20,120. 
These effectors then can hijack host cell signaling and manipulate host cell functions to benefit the 
bacteria 20,119,120. V. parahaemolyticus has one ancestral T3SS on chromosome I that is not 
important for human disease, and some strains, predominantly clinical isolates, have a second 
accessory T3SS encoded by one of three related Vibrio Pathogenicity Islands (VPaI): VPaIα, 
VPaIß, and VPaIγ 107. VPaIγ is a hybrid of genetic elements from both VPaIα and VPaIß 107, with 
the core content orthologous and syntenous with VPaIß 97,107. VPaIß and VPaIγ are divergent from 
VPaIα 107.  
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Worldwide, V. parahaemolyticus strains harboring the VPaIα, known as VPaI-7 106 in 
pandemic strain RIMD2210633 105, dominate infections. VPaIα is the most extensively studied 
VPaI with eight different T3SS effectors known and characterized: VopA/P, VopC, VopL, VopO, 
VopT, VopV, VopZ, and VPA1380 139,141,147,162.  Previous work had only established that VopV 
and VopZ were critical for enteric disease in an infant rabbit model 139,141,147,162, however, a recent 
study in germ-free mice has demonstrated that VopC not only promotes epithelial cell invasion 
during early stages of infection but also contributes to gastrointestinal pathogenesis 151.   
Strains harboring VPaIα rarely cause infections in the northeast United States. Instead, 
strains harboring VPaIγ, or occasionally VPaIß, are isolated from the majority of clinical cases 
(Figure 1.4) 11. Though VPaIß and VPaIγ encode a recognizable VopC homolog, the VopV and 
VopZ effectors encoded in VPaIß and VPaIγ are highly divergent from those characterized in 
VPaIα and in the case of VopV even lack key domains that promote actin remodeling 11. This 
suggests that unidentified effectors on VPaIß and VPaIγ could be primary virulence factors for V. 
parahaemolyticus strains harboring these islands. The goal of this study is to identify T3SS2 
effectors that are unique to VPaIγ that is associated with the clinically prevalent STs in the North 
Atlantic.  
T3SS effectors have a staggering level of diversity in structure with more than 75% of 
characterized effectors having no detectable sequence similarity to other known T3SS effectors 
202. The lack of sequence similarity makes consensus on structural patterns among the effectors 
challenging to parse out and difficult to predict. Despite this variation, computational analysis of 
known T3SS effectors indicates a modular composition with multiple functionally distinct 
domains or motifs 202,203. Effectors typically have three distinct regions: the amino-terminal 
secretion signal, followed by the optional chaperone-binding domain, and finally, the region that 
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harbors host cell effector activities 202–207.  In our study we utilized bioinformatic programs, some 
of which specialize in T3SS effectors, to analyze open reading frames (ORFs) on VPaIα, VPaIß 
and VPaIγ to predict  T3SS effectors, identify conserved domains, and calculate potential 
orthologs. We then employed biological assays to evaluate the putative effectors effect on 
eukaryotic cells to inform their potential significance during infection.  
 
Results and Discussion 
VPaIß and VPaIγ contain three putative effectors that are not present on VPaIα 
To identify effectors on VPaIs we utilized the bioinformatic program pEffect, which 
combines homology-based and de novo approaches to predict type III effector proteins 208. This 
program has a higher performance of identifying effectors over existing tools by identifying 
effector patterns throughout the protein sequence rather than just the N-terminus allowing for 
identifying a greater number and rapidly evolving effectors 208. To first evaluate the utility of this 
tool we tested it against the well-characterized VPaIα from strain RIMD2210633 that contains 
eight known effectors among its 83 ORFs, and in parallel analyzed representative VPaIß (from 
strain MAVP-R, MF066647.2) containing 88 ORFs and VPaIγ (from strain MAVP-Q, 
MF066646.1) containing 105 ORFs. The correct identification of known effectors from VPaIα 
indicates this tool’s reliability to classify ORFs as virulence effectors correctly. This analysis 
predicted three known effectors orthologous to VopA/P, VopC, and VopL, all previously 
characterized in the VPaIα of strain RIMD2210633 in all three VPaI (Table 2.1, Figure 2.1). The 
analysis also identified the known VPaIα effector VopO, 107. Similarly, it identified VPaIα effector 
VopV and also predicted that the highly divergent ORFs encoded in the same location of VPaIγ 
and VPaIß as effectors. However, pEffect failed to predict the known VPaIα effectors VopT 
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(VPA1327) and VopZ (VPA1336). Finally, this analysis identified five putative T3SS effectors 
among the ORFs in VPaIγ, all of which were also present in VPaIß but without identified homologs 




Table 2.1: Bioinformatic prediction of T3SS effectors.  
Effector name Locus ID pEffect Prediction BLASTx predicted ortholog 
Predicted Domains 
CDD SMART 
Characterized effectors   
VopA/P 
α: VPA1346 α:YES 69  PSI-BLAST 
α: T3SS YopJ 
family effector 
VopA 
α:  PRK15371, 
Acetyltransf_14 α:  -- 
ß: MAVP-
RPIeRC_00081 
ß: YES 67 PSI-
BLAST 
ß: multidrug DMT 
transporter permease ß: Acetyltransf_14 ß: LCR 
γ: MAVP-
QPI_00075 
γ: YES 69 PSI-
BLAST 
γ: multidrug DMT 
transporter permease 
γ: PRK15371, 
Acetyltransf_14 γ: -- 
VopC 
α: VPA1321 α: YES 70 SVM 
α: T3SS2 effector 
GTPase-activating 
deamidase VopC 
α:  CNF1, CNF1-like α:  LCR 
ß: MAVP-
RPIeRC_00083 ß: YES 83 SVM ß: Cytotoxin ß: CNF1 ß: -- 
γ: MAVP-
QPI_00077 γ: YES 70 SVM γ: Cytotoxin γ: CNF1, CNF1-like γ: -- 
VopL 




nucleation of actin 
polymerization  
α:  Drf_FH1 α:  WH2 (3), LCR (4) 
ß: MAVP-
RPIeRC_00080 ß: YES 93 SVM 
ß: Hypothetical 
protein/putative type 
III secretion system 
effector protein Vop 
ß: -- ß: WH2 (2), LCR (4) 
γ: MAVP-
QPI_00074 γ: YES 98 SVM 
hypothetical protein, 
WH2 motif family 
protein 
γ: -- γ:  WH2 (2), LCR (CT4291 3, MAVP-Q 4) 
VopO/ORF76 
α: VPA1329  α: YES 57 SVM α: Exoenzyme T  α:  -- α:  -- 
ß: MAVP-





ß: -- ß: -- 
γ: MAVP-
QPI_00076 γ: YES 68 SVM 
γ: hypothetical 
protein/conjugal γ: -- γ: -- 




α: VPA1327 α: NO α: Conjugal transfer protein TraA α:  ADPrib_exo_Tox α:  -- 
      
      
VopV 
α: VPA1357 α: YES 87 SVM α: Hypothetical protein  
α:  Glutenin_hmw, 
PRK07764 (2) 
α:  Transmembrane region, 
LCR (4) 
ß: MAVP-
RPIeRC_00066 ß: YES 72 SVM 
ß: Hypothetical 
protein ß: -- 
ß: transmembrane region, 
LCR (15) 
γ: MAVP-
QPI_00061 γ: YES 87 SVM 
γ: Hypothetical 
protein  γ: Treacle (2) PRK07764 
γ: transmembrane region, 
LCR (22) 
VopZ 
α: VPA1336 α: NO α: Hypothetical protein  α:  -- α:  LCR 
ß: MAVP-
RPIeRC_00049 ß: NO 
ß: Hypothetical 
protein ß: -- ß: LCR (2) 
γ: MAVP-
QPI_00044 γ: NO 
γ:  Hypothetical 
protein γ: -- γ: LCR (2) 
VPA1380/ORF32 
α: VPA1380 α: YES 70 PSI-BLAST   α: OspB protein α:  PTZ00440 α:  -- 
ß: MAVP-
RPIeRC_00039 





ß: -- ß: LCR 
γ: MAVP-
QPI_00032 





γ: -- γ: LCR 
Putative effectors   
ORF34 
          
ß: MAVP-
RPIeRC_00041 ß: YES 96 SVM 




Peptidase_M60, M60-like ß: M60-like, LCR 
γ: MAVP-









γ: M60-like, transmembrane 
region, LCR 




          
ß: MAVP-
RPIeRC_00042 ß: 81 YES SVM 
ß: hypothetical 
protein ß: -- ß: -- 
γ: MAVP-
QPI_00035 γ: YES 72 SVM 
γ: hypothetical 
protein γ: -- γ: LCR 
ORF81 
          
ß: MAVP-
RPIeRC_00087 ß: YES 80 SVM 
ß: hypothetical 
protein ß: -- ß: -- 
γ: MAVP-
QPI_00081 γ: YES 87 SVM 
γ: hypothetical 
protein γ: -- γ: LCR 
 Prediction of T3SS2 effectors by pEffect..Gene names provided to the orthologs named  strain RIMD2210633 VPaIα (NC_004605 region between 
VPA1312 and VPA1395), designated as α, strain MAVP-R VPaIß (MF066647.2), designated as ß, and strain MAVP-Q VPaIγ (MF066646.1), designated 
as γ. “+” = the presence of effector and predicted effector on VPaIα/ß/γ. “-” = the absence of effector and predicted effector on VPaIα/ß/γ.  “~” = divergence 
between orthologs found in VPaIß/γ compared to the characterized effector in VPaIα. Basic Local Alignment Search Tool (BLASTx) and protein domains 
and motifs predicted from SMART (Simple Modular Architecture Research Tool)209 and NCBI’s Conserved Domain Database (CDD)210 are detailed. 
LCR = Low Complexity Region; DUF = Domain of Unknown Function. 
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Figure 2.1. Comparison of content and conservation in representative VPaIα, VPaIβ, and 
VPaIγ. Named effectors from VPaIα (vopA/C/L/V/Z and VPA1380) and their homologs are light 
green. Candidate T3SS2β effectors (including divergent vopV and vopZ homologs) are red. The 
program pEffect and BLASTp searches predicted candidate effectors. Figure adapted from Xu et 
al. 2017 107.  
 
Protein domains and analogs predict function and support the identity of predicted T3SS 
effectors 
Whereas one predicted effector, ORF32, was identified by homology to a characterized 
effector, the remaining four effectors, ORF34, 35, 76, and 81 were de novo predictions via Support 
Vector Machines (SVM) machine learning 208,211 (Table 2.1). Attempts to assign potential names 
to these four by identifying homologous proteins using in the NCBI non-redundant protein 
database identified the unnamed predicted effectors only as hypothetical proteins. Three predicted 
effectors (ORF32, 34, and 76) were homologous to named proteins present in other Vibrio spp. 
including Vibrio cholerae, Vibrio harveyi, Vibrio diabolicus, Vibrio mimicus, and Vibrio 
campbellii.  
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Among the predicted effectors, only ORF32 was initially identified based on sequence 
similarity-based inference by PSI-BLAST (Table 2.1).  Though the identifying T3SS effector 
protein EspS was from Citrobacter rodentium (35.7% sequence identity, 94% query coverage, 
3x10-40 E-value) further analysis revealed ORF32 was homologous to the OspB effector encoded 
by Shigella spp. 212 (35.2% sequence identity, 88% query coverage, 1x10-31 E-value), and more 
strikingly to a previously identified T3SS2 effector from VPaIα, VPA1380 (43.5%, 93% query 
coverage, E-value of 9x10-76) 166. ORF32 and VPA1380 were not identified as homologs 
previously107 based on the low deduced protein identities, but the high E-value supports that these 
are evolutionarily related. EspS helps maintain physiological balance during mouse infection by 
repressing colonic crypt hyperplasia 213. OspB, in Shigella pathogens helps repress the host 
inflammatory response via down-regulation of IL-8 214, and activates the NFkB pathway 215. In 
contrast to OspB, which produced limited, stress-dependent toxicity in Saccharomyces cerevisiae, 
the OspB homolog VPA1380 (with 50% similarity) was toxic in yeast 166. Thus, researchers 
predicted that VPA1380 might target different eukaryotic pathway than OspB during normal S. 
cerevisiae growth  166.  
Next, to identify these putative effectors’ functional domains, the architecture of the deduced 
proteins were analyzed by two protein domain prediction programs 209,210.  The deduced protein 
sequence of ORF76 had no conserved domains. The only potential domains in ORFs 32, 35, and 
81 were Low Complexity Regions (LCRs), whose biased amino acid composition can lead to  more 
predicted binding partners across different Protein-Protein Interaction (PPI) networks 216. Some 
LCRs have identified roles, but the functions of most are not known 216–220. Previous studies of 
repetitive sequences, such as those in LCRs, suggests that this genetic pattern enables rapid 
adaptation to new environments 216,218,221,222. Although the LCRs in ORFs 32, 35, and 81 have no 
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further information, perhaps these domains provide a yet to be determined function. Of the five 
predicted T3SS effectors, pEffect assigned the highest probability score to ORF34. Searches for 
related proteins suggest ORF34 is most similar to proteins identified as sugar ATP-binding cassette 
(ABC) transporter substrate-binding protein. Predicted functional domains in ORF34 include a 
transmembrane helix region, a Pfam DUF (Domain of Unknown Function), and an M60-like 
domain (Figure 2.2). Bacteria secrete T3SS effectors into either the plasma membrane or directly 
into the cytosol of the target cell; thus, this transmembrane region of ORF34 could allow for 
effector binding to eukaryotic membranes 223. M60-like domains typically possess mucinase 
activity, which could be beneficial in breaking down the protective mucin layer produced by 
enterocytes to allow for better bacterial adhesion 224. Pfam DUF4092 is in other Proteobacteria 
such as Escherichia coli, Vibrio cholerae, Vibrio fischeri, and Photobacterium iliopiscarium 225. 
Similarly to ORF34, 18 of the 20 known proteins with Pfam DUF4092 also contain the Peptidase 
M60-like domain downstream, and most are identified as Accessory colonization factor (AcfD) 
homologs. During infection, AcfD promotes efficient intestinal colonization in the human enteric 
pathogens V. cholerae 226 and Enterotoxigenic E. coli (ETEC) 227. In V. cholerae, AcfD is a lipid 
anchor at the cell membrane, which also hints at the function of the predicted transmembrane helix 
region in ORF34. In ETEC, the AcfD homolog, YghJ, is a metalloprotease that influences 
intestinal colonization of ETEC by degrading the major mucins in the small intestine 227. The 
similar functional domains as other enteric pathogens shed some light as to the possible function 
of ORF34. The close proximity (37bp apart) and directionality of two putative effector genes, 
ORF34 and ORF35, suggest these are likely co-transcribed under a single promoter’s control. No 
transcriptional terminators were identified 228 within 300nts downstream of ORF35, but one was 
identified after ORF34.  




Figure 2.2: ORF34 contains predicted domains that may influence successful colonization.  
ORF34 domain prediction from SMART (Simple Modular Architecture Research Tool) 209. The 
blue rectangle indicates a transmembrane region. Pfam DUF4092 is in the Protein family “Domain 
of Unknown Function” 4092. The teal pentagon indicates the M60-like domain. The pink rectangle 
indicates a Low Complexity Region (LCR). 
 
There were no predicted domains for ORF76, but its possible function may be gathered from 
its homology to known proteins. ORF76 was homologous to a conjugal transfer protein TraA of 
V. parahaemolyticus (100% sequence identity, 99% query coverage, 7x10-164 E-value), and several 
deduced TraA proteins from other members of the Vibrionaceae family. TraA is typically involved 
in pilus biosynthesis and assembly during conjugation 229.  Understandably, pEffect identified 
ORF76 as a potential T3SS effector since some T3SS apparatus proteins are identified as effectors 
by pEffect. For example, the translocator VopD2 (VPA1361) 230 and translocon protein VopW 
(VPA1345) 231 were both predicted by pEffect to be T3SS effectors via SVM (scores of 82 and 94 
respectively). These proteins are part of the secretion needle and extend from the bacterial cell into 
its target, similarly to TraA’s role as a pilin precursor protein 229. Homology to TraA does not 
suggest that ORF76 has a toxin-related role during infection, but further studies such as secretion 
assays and animal studies would be necessary to make this determination. Interestingly though 
ORF76 as a was not previously identified as homologous to to the  VPaIα effector VopO 
(VPA1329) based on sequenced identity (46.05% sequence identity, 99% query coverage), the 
strong E-value (1x10-75) provides statistical support of evolutionary relatedness. During 
gastrointestinal infection with V. parahaemolyticus, VPA1329 contributes to host epithelial 
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disruption by activating the RhoA-ROCK signaling pathway, which induces actin stress fiber 
formation 145. But, VPA1329 was not considered a primary effector during infection of rabbit illeal 
145. Due to the recent findings of the contribution of VopC in a mouse infection model 151, further 
investigation into ORF76 is necessary to understand its role fully. Unlike with ORF32, 34 and 76, 
searches for homologs provided little insight into the function of the remaining two effectors, ORF 
35 and ORF81. 
VPaIß and VPaIγ encode potential homologs of the VPaIα-encoded effectors critical for the 
enterotoxicity of pandemic strains, VopV (VPA1357) and VopZ (VPA1336). Previous analysis 
using Roary 232 indicated VopV and VopZ did not meet the 50% threshold used for identifying 
homologs between VPaI even though divergent ORFs located in the same location and gene 
neighborhoods in VPaIß and VPaIγ were still considered potentially analogous 11. A closer 
examination and comparison of the deduced VopV protein in VPaIα (VPA1357) to the potential 
analog in VPaIγ (ORF61) indicates that even though they share only 40.3% protein sequence 
identity with 60% query coverage, the accompanying E-value of 6x10-95 provides strong statistical 
support of homology. Although the lower query coverage could be related to size differences of 
the deduced VopV proteins (VPA1357 at 4869bp and ORF61 at 7209bp), size alone does not 
account for this poor coverage. VopV encoded by VPA1357 possesses multiple domains, the 
interspersed or long repeat domains (rep1/2/3) and C-terminal domain, that are crucial to VopV 
induced enterotoxicity 139,141. These domains bind to actin filaments and the actin-cross linking 
protein filamin 139. Thereby bundling actin in the host cell leading to rearrangement of the apical 
epithelial cell membrane and elimination of the actin-filled microvilli brush border, leading to 
enhanced adhesion of V. parahaemolyticus to the host cell 139,141.  Alignment of VPA1357 and 
ORF61 proteins indicate that these important domains in VPA1557 are either not present in ORF61 
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or contain numerous amino acid composition changes. The large discrepancy in these important 
domains could indicate that ORF61 does not have the same enterotoxic capabilities as its 
characterized homolog VPA1357.  
The VopZ analogs are relatively similar in size, with VopZ from VPaIα (VPA1336) 753bp and 
the potential VopZ analog in VPaIγ (ORF44) 768bp. Despite their similarity in size, VPA1336 
and ORF44 have only 27% protein percent identity (71% query coverage) though again, the strong 
E-value (1x10-15) indicates evolutionary relatedness. V. parahaemolyticus induced diarrhea and 
other intestinal pathology, but not colonization, in vivo relies on amino acids 38–62 in VPA1336 
147. When the proteins are aligned, only 32% of this important region in the VPA1336 sequence is 
retained in ORF44. There is also a deletion of one amino acid and an insertion of four amino acids. 
This divergence in sequence in this important domain in ORF44 from the characterized VPA1336 
might contribute to changes in intestinal pathology during V. parahaemolyticus infection. Previous 
studies indicate that truncation of VPA1336 after amino acids 38–62 resulted in the loss of V. 
parahaemolyticus colonization of the small intestine 147.  Since this region is important for V. 
parahaemolyticus colonization perhaps the large divergence in sequence from VPA1336 
effectively removed this capability of ORF44. Since ORF61 and ORF44 on VPaIγ are so divergent 
from their enterotoxic orthologs on VPaIα, this suggests that further investigation is needed to 
assess which effectors contribute to V. parahaemolyticus pathogenicity.   
 
Predicted effectors are toxic to eukaryotic cells 
To examine putative effector toxicity towards eukaryotic cells, we used heterologous 
overexpression in the yeast S. cerevisiae and quantified growth inhibition following protein 
induction.  Yeast is often used as part of T3SS effector characterization since they utilize conserved 
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eukaryotic processes that are typical targets of T3SS effectors, such as cell signaling and 
cytoskeletal dynamics, without immunity mechanisms that counteract T3SS effectors 233–235. Due 
to this, while effector toxicity as inferred by growth attenuation by heterologous effector 
expression in yeast, does not directly recapitulate all aspects of enterotoxicity or disease, the model 
is an excellent initial screen to evaluate proposed effectors and gain initial insight into the role an 
effector might have on their eukaryotic target.   
During intracellular overexpression of each putative effector, relative toxicity was 
quantified by their ability to inhibit yeast growth  compared to negative (empty vector) and positive 
(VopA) controls. When grown under inducing conditions, the ORF32 construct did not reduce 
yeast growth, similarly to the yeast harboring the empty vector (Figure 2.3). In contrast, induction 
of ORF35 and ORF81 dramatically reduced yeast growth. Expression of ORF34 and ORF76 
moderately attenuated yeast growth. In congruence with previous studies 124, the VopA homolog 
inhibited yeast growth,  the VopC homolog did not attenuate yeast growth. Finally, VopL was not 
previously evaluated for yeast toxicity, and its homolog from VPaIγ did not inhibit yeast in our 
study.  
Even though a key VPaIα effector, VopZ is highly divergent from gene products in the 
same location in VPaIß/γ, these were both identified as putitive effectors and may be analogous 
toxins, and thus both were evaluated for toxicity. Neither VopZ analog from VPaIα (VPA1336) 
nor VPaIγ (ORF44) inhibited yeast growth. During V. parahaemolyticus infection, VopZ from 
VPaIα promotes colonization by inhibiting the activation of the kinase TAK1, which disrupts cell 
signaling cascades leading to phenotypes such as inflammation, distorted epithelial structure, and 
mislocalization of tight junction proteins 125,147,163. Yeast do not exhibit these phenotypes, thus this 
model cannot appropriately evaluate the effect of these proteins. While this does limit this model’s 
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effectiveness for evaluating some characteristics of epithelial disease, the wide breadth of effectors 
that the model can evaluate, such as those that alter the cytoskeleton and organelles, target MAPK-
signaling cascades, or perturb vesicle trafficking warrants this as an effective preliminary assay 
234. Other assays useful in evaluating effectors whose effect cannot be visualized in yeast include 
more laborious assays such as Western Blot analysis, cell-culture, and animal models. Despite the 
minimal growth reduction conferred by ORFs 32 and 34, these effectors could still contribute to 
disease if their eukaryotic target does not confer a similar phenotype in yeast, similar to the finding 
of VopZ. Other models including cytotoxicity 122 and brush border remodeling139 of cultured 
human colon cells, and animal infection models such as the rabbit ileal loop model 98,138 or a mouse 
infection model151 are needed to address this issue. We did not evaluate VopV in this model due 
to its large size and the repetitive nature of the sequence that thwarted our attempts to clone the 
gene.  
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Figure 2.3: Heterologous expression of putative effectors inhibit yeast growth. Serial dilutions 
of yeast transformed with pYES2.1 plasmid harboring putative toxin (from VPaIγ or VPaIα) were 
grown under non-inducing (glucose) and inducing (galactose) conditions. Data is representative of 
three experiments performed in triplicate. All effectors except VPaIα VopZ were constructed from 
ST631 clade II MAVP-Q harboring VPaIγ genomic DNA. VPaIα VopZ template DNA was ST3 
MAVP-C harboring VPaIα genomic DNA.  
 
Predicted effectors induce cytotoxicity in cultured human colon cells 
Next, we assessed T3SS2-dependent cytotoxicity of each putative effector against cultured 
Caco-2 colorectal tumor cells. Caco-2 cells were co-cultured with wild-type (wt) V. 
parahaemolyticus and with mutant derivatives altered for T3SS ability. After co-culture, the 
cytotoxicity of the Caco-2 cells was quantified (Figure 2.4). Effectors secreted by T3SS1 
contribute to cytotoxicity towards Caco-2 cultured cells, but are unimportant for enterotoxicity and 
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can mask the effect of T3SS2 effectors. For this reason, the vscN1 gene encoding the ATPase 
powering secretion through the T3SS1 apparatus was deleted to disable T3SS1 effector secretion 
prior to the generation of individual effector gene deletions. We included this derivative to 
eliminate background cytotoxicity, allowing us to evaluate each putative effector’s contribution to 
cytotoxicity. All V. parahaemolyticus strains were cultured in 0.04% bile before co-incubation 
with Caco-2 cells to simulate gastrointestinal conditions and induce differential regulation of 
virulence genes 236–238. However, a recent study indicates that genes on VPaIγ in strain 04-1290 
were not induced by bile, though the assertion that strain 04-1290 containing VPaIγ did not contain 
bile-inducible VtrABC was not correct 107,238,239. In our study, V. parahaemolyticus growth in bile 
increased cytotoxicity towards Caco-2 cells (data not shown), and thus bile was used for all 
experiments. Elimination of VscN1 (ΔvscN1) did not significantly reduce cytotoxicity under the 
conditions of our assays (Figure 2.4), as expected from previous data 9. This importantly alludes 
to the substantial impact of toxic effectors from T3SS2 contributing to the cytotoxicity of Caco-2 
cells, and the utility of the model. This is further borne out by the elimination of T3SS2 in the 
T3SS1 mutant background, which significantly impaired cytotoxicity, reflective of an inability of 
these bacteria to secrete T3SS2 toxins, again replicating previously published work 9. Following 
this validation, we subsequently eliminated predicted T3SS2 effectors, as well as ORF61 (VopV) 
and ORF44 (VopZ), and evaluated their impact on cytotoxicity. Notably, we did not generate 
individual ORF34 or ORF35 deletions because we predicted that these ORFs are cotranscribed 
under the control of a shared promoter, thus both ORFs were eliminated simultaneously generating 
the mutant designated ΔORF34-35 .     
Elimination of the OspB/VPA1380 homolog ORF32 did not attenuate cytotoxicity, 
however, elimination of any of the remaining putative toxins, or the combined elimination of 
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ORF34 and ORF35, significantly reduced cytotoxicity (P > 0.01) compared with either wild type 
or the parental T3SS1 mutant.   Taken together, these results along with the ability of these toxins 
to inhibit yeast growth suggest that putative effectors ORFs 34-35, 76, and 81 are four of the genes 
responsible for T3SS2-dependent cytotoxicity, along with the vopV and vopZ analogs (ORFs 61 
and 44 respectively). Interestingly eliminating any singular putative toxin appears to reduce the 
cytotoxicity to similar levels as preventing the secretion of all T3SS2 effectors. Since VPaIα 
effectors work in concert to achieve their enterotoxic effect, we believe that our cytotoxicity model, 
as a surrogate for enterotoxicity, could work similarly, in that deletion of one effector affects the 
ability of other effectors to carry out their function.  
Figure 2.4. Reduced cytotoxicity towards Caco-2 cells mirrors the difference in toxicity 
towards yeast. The human colorectal tumor cell line, Caco-2 cells, were co-incubated with V. 
parahaemolyticus strains defective in T3SS1, and harboring indicated ORF deletions. We predict 
ORFs 34 and 35 are co-transcribed and thus deleted both simultaneously. Percent cytotoxicity, 
estimated by the quantity of lactate dehydrogenase (LDH) in the well after co-culture, was 
calculated by the following equation: [optical density at 490 nm (OD490) of experimental release - 
OD490 of spontaneous release]/(OD490 of maximum release - OD490 of spontaneous release)*100%. 
Spontaneous release is the amount of LDH released from the cytoplasm of uninfected cells.  The 
maximum release is the total amount of LDH released after the complete lysis of uninfected cells. 
* = p <0.001 Tukey Kramer HSD for pair-wise comparisons. Data represents the mean ± standard 
deviation from one experiment using five individual bacterial colonies per strain, performed in 
triplicate. The experiment was repeated twice with similar results. 
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Conclusion 
Critical forces on microbial pathogen’s evolution are gene gain or loss, and recombination 
of acquired genes 32,55,57–62. Acquisitions of genetic material, such as virulence effectors, can 
provide a fitness advantage beneficial to bacteria under certain conditions such as adaptation to 
changing environmental conditions, enhancing virulence, or immune evasion 32,34,56,57,64–66. 
Virulence effectors can also undergo strong selection for either increasing allelic variation, 
maintaining a beneficial allele, and removing deleterious alleles 240. Diversity in effector content 
can be beneficial for bacteria, because each toxin has a particular function. While some may be 
more important than others in a given environment, they all have a specific role that may benefit 
the bacteria, especially when they work in concert 112,240,241.  
In addition to confirming the presence of homologs of four named effectors in VPaIα 
(VopV, VopZ, VopO and VPA1380) that eluded prior discovery, we also identified three T3SS2β 
effectors encoded in VPaIγ and β without homologs in VPaIα, all of which may contribute to 
disease caused by the most clinically prevalent strains in North America, including ST631 and 
ST36. The protein domains and cytotoxicity induced by ORF34 suggest it could be an important 
effector and promote enterotoxicity. The transmembrane anchoring, mucinase activity, and 
enhanced colonization associated with these domains characterized in other enteric pathogens 
suggest that ORF34 may contribute these same characteristics to V. parahaemolyticus during 
infection. Mucus and mucins are the first line of defense for enterocytes 242,243; thus, mucin-
degrading capabilities by V. parahaemolyticus would be extremely beneficial to infection success. 
These predicted activities may also explain the lack of toxicity in yeast.  The likely co-transcribed 
protein ORF35 was toxic to yeast and likely contributed to Caco-2 cytotoxicity; however, 
individual gene deletions are needed to identify if cytotoxicity was due to the synergistic effects 
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of ORF34 and ORF35, or just ORF35. Caco-2 cells do not secrete mucins 244,245, thus if mucin-
degradation is the primary role of ORF34, then the cytotoxic effect seen can be attributed to 
ORF35. The quantification of mucus degradation after co-culture with a mucus-producing cell line 
such as HT29-MTX could assess this hypothesis 244–246. The cytotoxicity of ORF76 and ORF81 
towards both yeast and human colon cells indicates that these effectors are toxic toward cultured 
human colon cells, suggesting a potential role during infection in humans. ORF32 was the only 
effector predicted by pEffect based on nucleotide sequence similarity to other known T3SS 
effectors, but it did not inhibit yeast growth and is not cytotoxic towards cultured human colon 
cells. Thus, we believe other models for ORF32’s characterization are more appropriate, and 
further studies are needed. These effector’s impact in the models utilized lays important 
foundational work towards virulence effector identification and characterization in VPaIγ. To 
elucidate the contribution these effectors have towards disease, infection analyses such as human 
colon cell brush border effacement 139, or gastrointestinal colonization and pathogenesis studies in 
infant rabbits138,139 or mice 151 are necessary.  
Identification of the virulence effectors in the prominent pathogenic V. parahaemolyticus 
lineages in North America could aid in monitoring local populations. This, combined with tdh  and 
trh monitoring, can be translated into sensitive surveillance tools to identify the most important 
emergent lineages, which can prevent negative publicity and reactive harvest closure of local 
businesses 247–249. These findings can also inform therapeutic interventions and novel vaccines 
beneficial for individuals with an increased risk for infection 250. This study identifies V. 
parahaemolyticus T3SS effectors on VPaIβ and VPaIγ, but it does not fully characterize each 
effector’s role during gastrointestinal infection. Though we do identify effectors encoded by VPaIβ 
and VPaIγ, there are different lineages of VPaIγ that have evolved in geographically distinct 
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populations, and strains that harbor these variants differ in clinical prevalence 11. T3SS effectors 
on VPaIα are essential for disease, thus since there is variation in clinical prevalence among VPaIγ, 
perhaps this is due to variation in their T3SS effectors. Further studies are needed to examine 
whether the variation in these five T3SS effectors on VPaIβ and VPaIγ correlate with clinical 
prevalence of their harboring strains.  
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Materials and Methods 
Bacterial and Yeast Strains, Media and Culture Conditions 
The bacterial strains and plasmids used in this study are described in Table 2.2 and Table 2.3, 
respectively. V. parahaemolyticus was routinely grown at 37°C in Luria-Bertani medium 
supplemented with 2% NaCl (LBS) 251 or in defined minimal media 252 supplemented with 
0.0058% K2HPO4, 0.1% NH4Cl, 0.01mM FeSO4, 0.1 mM Tris pH 7.4, 0.6% glycerol, 1x Artificial 
Sea Water, 0.625µg/mL chloramphenicol, and tap water for trace minerals for transformation.  E. 
coli strains were grown at 37°C in Luria-Bertani medium (LB) as previously described 251. 
Antibiotics were supplemented for selection of mutations and plasmids at the following 
concentrations for V. parahaemolyticus: 12 µg/ml gentamicin (Gen), 2.5 µg/ml chloramphenicol 
(Chl), and 5 µg/ml erythromycin (Erm) and at the following concentrations for E. coli: 50 µg/ml 
kanamycin (Kan), 100 µg/ml ampicillin (Amp), and 25 µg/ml chloramphenicol (Chl).  
S. cerevisiae BY4742 (obtained from Clyde Denis, 253) was maintained in yeast extract (1%)-
peptone (2%)-and dextrose (2%) medium (YPD) 253, and grown on Synthetic Complete Minimal 
Media (SC-MM) made with Yeast Synthetic Drop-out Medium Supplements without uracil 
(Sigma-Aldrich), supplemented with glucose at 2% once transformed with pYES2.1/V5-His-
TOPO®. S. cerevisiae was grown at 28°C.  
 
Bioinformatic Analyses 
The annotated VPaIs, including VPaIα (from strain RIMD2210633, NC_004605 region between 
VPA1312 and VPA1395), VPaIß (from strain MAVP-R, MF066647.2) and VPaIγ (from strain 
MAVP-Q, MF066646.1), were analyzed by the pEffect online algorithm 208. The predicted T3SS 
ORFs from pEffect were then submitted individually to the following programs according to their 
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normal operating instructions: Basic Local Alignment Search Tool (BLASTx) 254, SMART 
(Simple Modular Architecture Research Tool) 209, and NCBI's Conserved Domain Database 
(CDD) 210. To find potential terminators, the 300 nucleotide region following the stop codon of 
ORF35 and ORF34 was submitted to the FindTerm (Softberry Inc.) 228 webpage application set to 
standard operating instructions with the “All putative terminators” box checked.  
 
Molecular genetic methodologies and plasmid construction 
Strain Construction Overview 
Targeted deletion mutants of V. parahaemolyticus strains were constructed through the process of 
PCR Splicing by Overlap Extension (SOE) 255 wherein genes of interest were eliminated and 
replaced with an antibiotic resistance cassette, the resulting constructs were cloned into plasmid 
pCR2.1 TOPO (TOPO™ TA Cloning™ Kit, Thermo Fisher), which was subsequently used for 
natural transformation. PCR SOE primers have 3’ complementary ends to the products intended 
to fuse together (Table 2.2). During PCR cycling, the ends overlap and are extended into a single 
molecule. 
 
PCR SOE and cloning 
Primers for generating constructs used in marker exchange mutagenesis were designed as 
recommended 255. Oligonucleotide primers were synthesized by © Integrated DNA Technologies 
(Coralville, IA). PCR cycling conditions were optimized using AccuStart II PCR SuperMix 
(Quantabio, Beverly, MA). Genomic DNA from V. parahaemolyticus strain MAVP-Q, a ST631 
clade II member containing VPaIγ, from VPaIγ,  and  strain MAVP-C, a pandemic ST3 strain 
containing VPaIα,was used as a template to generate amplicons upstream and downstream of the 
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gene of interest, whereas amplicons of the antibiotic cassettes were generated using plasmids 
pBD4 and pEVS170 (Table 2.4). Genomic DNA was prepared by organic DNA extraction 256. 
Oligonucleotide primers for gene knockouts were designed to contain at least 400bp regions 
flanking the gene of interest to enable efficient recombination (Table 2.3). Oligonucleotide primers 
for the antibiotic cassette to replace the gene of interest were designed to contain the native 
antibiotic resistance cassette promoter from the plasmid (Table 2.3). Analysis of the secondary 
structure of primers was performed by NetPrimer (©PREMIER Biosoft). Gene knockouts and 
antibiotic resistance genes were amplified from target DNA with Phusion® High-Fidelity DNA 
Polymerase or Phusion® High-Fidelity PCR Master Mix (©New England Biolabs, Ipswich, MA) 
according to ©New England Biolabs Inc. protocol. PCR SOE was performed as described 255.  
PCR SOE product was cloned into pCR2.1TOPO® and transformed into chemically competent E. 
coli 10-beta cells (New England Biolabs®, Ipswich, MA) following Invitrogen pCR2.1TOPO®  
(Invitrogen K202020) protocol. Plasmid DNA was purified using ©QIAGEN Plasmid Kit protocol 
with house-made ©QIAGEN reagents. Confirmation that the constructs contained no PCR 
generated errors was determined by sequencing using the Sanger method by ©GENEWIZ LLC 
(South Plainfield, NJ, USA).  
 
Competency Plasmid Construction 
To enhance the competency of V. parahaemolyticus enabling the use of natural transformation for 
strain construction, we designed and constructed a plasmid to express the native tfoX gene from V. 
parahaemolyticus strain MAVP-Q under the control of the arabinose-inducible and glucose-
repressible promoter PBAD along with the gene encoding the arabinose operon regulatory protein 
araC gene (araC-ParaBAD-tfoX) into shuttle vector pEVS79, generating pSEE1. Briefly, primers 
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were designed to clone the araC and its native promoter and a downstream ParaBAD promoter from 
pSW7848, and in parallel to amplify the native V. parahaemolyticus tfoX from MAVP-Q, and the 
two amplicons were fused using PCR SOE 255. The resulting construct was cloned into 
pCR2.1TOPO plasmid, which was propagated in E. coli One-Shot TOP10. Purified plasmids were 
sequenced to confirm the constructs were correct and error-free by Sanger sequencing at 
©GENEWIZ LLC (South Plainfield, NJ, USA). The araC-ParaBAD-tfoX cassette was subsequently 
cloned from the resulting plasmid (pSEE21) into pEVS79 257 by restriction digest with SpeI and 
XhoI (©New England Biolabs, Ipswich, MA) to move the cassette from pSEE21 to pEVS79 257, 
resulting in the final plasmid pSEE1. pSEE1 was conjugated into V. parahaemolyticus using Tri-
Parental Mating with the helper plasmid pEVS104 as described 257. Briefly equimolar 
concentrations of mid-log phase E. coli harboring pSEE1, E. coli harboring pEVS104, and 
recipient V. parahaemolyticus were individually washed in LBS and resuspended together in 20 
µL LBS. The entire suspension was spotted onto LBS agar and grown overnight at 37°C. The 
following day entire spot was collected, diluted, plated onto LBS+Chl2.5, and grown at 28°C 
overnight to select for V. parahaemolyticus. 
 
Transformation of V. parahaemolyticus 
V. parahaemolyticus strains harboring pSEE1 were grown to turbidity in LBS and subsequently a 
2% inoculum was used to grow an overnight culture at RT in minimal medium supplemented with 
0.2% arabinose. Once cultures reached OD600 > 0.5, 0.5 mL culture was mixed with 2 µg of either 
plasmid DNA or ~10 µg of genomic DNA that was sheared by freeze-thaw three times at -20°C, 
and incubated at 28°C statically for 30 minutes. 0.5 mL LBS was added to the culture and was 
incubated at 37°C for 20-60 minutes. Cells were pelleted and suspended in ~50 µl LBS broth. 
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Equal volumes of transformant were plated onto three concentrations of antibiotic flanking 
estimated optimal concentration (10/12/15 µg/ml gentamycin and  2.5/5/8 µg/ml erythromycin) 
and grown at 37°C overnight. Colonies were re-streaked to a plate with a higher concentration of 
antibiotic, grown at 37°C, then the colony screened by PCR to identify the presence of the 
mutation. Mutants harboring pSEE1 were passaged at a 2% inoculum in LBS twice per day for 
two days to lose plasmid.  
 
Cytotoxicity Assay 
Eukaryotic cell culture 
Caco-2 cells were regularly maintained in Dulbecco’s modified Eagle’s medium (DMEM, 
ATCC®) containing 10% (v/v) Fetal Bovine Serum (FBS, Sigma®) and Corning® Antibiotic-
Antimycotic Solution at 37°C in 5% CO2.  
 
Cytotoxicity measurements 
Caco-2 cells at 80% confluency were washed in DMEM without phenol red + 10% FBS and seeded 
25µL of cells at 315 cells/µl in 384-well plates and cultured for 48hr at 37°C in 5% CO2 to 
confluency. Unmodified V. parahaemolyticus strains were streaked for isolation onto LBS agar, 
ΔvscN1:Gen V. parahaemolyticus mutants were streaked for isolation onto LBS + 5 µg/ml Gen, 
and ΔvscN1:Gen/Δ(gene of interest):Erm V. parahaemolyticus mutants were streaked for isolation 
onto LBS + 5 µg/ml Erm. All V. parahaemolyticus strains were grown at 37°C until robust colony 
growth. Five colonies of V. parahaemolyticus were grown overnight in LBS + 0.04% bile salts at 
37°C in a roller drum. Cultures were washed twice in PBS and diluted to add 5µL of culture to 
48hr Caco-2 cells at an MOI of 10. Three replicates per sample were added to Caco-2 cells. After 
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6hrs of co-culture, the release of lactate dehydrogenase (LDH) into the medium was quantified by 
using a CytoTox96® non-radioactive cytotoxicity kit (Promega®) according to the manufacturer’s 
instructions. To quantify percent cytotoxicity, the LDH release was calculated with the following 
equation: [optical density at 490 nm (OD490) of experimental release - OD490 of spontaneous 
release]/(OD490 of maximum release - OD490 of spontaneous release)*100%. Spontaneous release 
is the amount of LDH released from the cytoplasm of uninfected cells, whereas the maximum 
release is the total amount of LDH released after the complete lysis of uninfected cells. 
Statistical Analysis 
Data from Caco-2 cytotoxicity assay represents the mean ± standard deviation from one 
experiment using five individual bacterial colonies per strain, performed in triplicate. Pairwise 
comparison across strains was performed utilizing Tukey Kramer HSD. 
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Table 2.2: Strains used in this study 
Strain Description Source of Reference 
E. coli strains     
  DH5α pEVS79 257 
  CC118lpir pEVS104 257 
  TOP10 pSEE1 This study 
 One-Shot TOP10F’  Thermo Fisher® 
 10-beta cells  New England Biolabs® 
        
V. parahaemolyticus 
strains     
  MAVP-Q WT 22 
  TBD ΔvscN1:Gen This study 
  TBD ΔvscN1:Gen ΔvscN2:Erm This study 
  TBD ΔvscN1:Gen ΔORF32:Erm This study 
  TBD ΔvscN1:Gen ΔORF34-35:Erm This study 
  TBD ΔvscN1:Gen ΔORF85:Erm This study 
  TBD ΔvscN1:Gen ΔORF90:Erm This study 
  TBD ΔvscN1:Gen ΔvopV:Erm This study 
  TBD ΔvscN1:Gen ΔvopZ:Erm This study 
        
S. cerevisiae strains     
  BY4742 his3-Δ1 leu2-Δ0 ura3-Δ0 lys2-V0 
253 




Table 2.3: Oligonucleotides used in this study. 
Primer name Target Gene DNA template Sequence 
Yeast Toxicity Assay       
  32YES FRBS2 ORF32 MAVP-Q gDNA AAAATGGCTATCTCTTTAACCGGATGTTT 
  32YES R  ORF32 MAVP-Q gDNA GGTCAGAGCCTCATTGTTGATATTAGTCC  
  PrSEE52 34YES FRBS2 631_674 ORF34 MAVP-Q gDNA TTGATGGTTTGTTTTTCAGGTTTTTTC 
  PrSEE53 34YES R2 631_674 ORF34 MAVP-Q gDNA TACAACTAGTCTCCAGCCTAATGTACCGT 
  35YES FRBS  ORF35 MAVP-Q gDNA GAAATGGGTATTATGATTCCTACATTCAACAGAG 
  35YES R ORF35 MAVP-Q gDNA CTAAAATCAAATCCTTTCTATCAATGTTCACT 
  85YES FRBS  ORF76 MAVP-Q gDNA ACTATGGCTTTAAATAAAATAAACCCTATTCAGT 
  85YES R  ORF76 MAVP-Q gDNA CAGGAAACTCTACTAACACAAAAGAAGCC  
  90YES FRBS  ORF81 MAVP-Q gDNA AAAATGGTAATACAAAGCCAAAGACTGAGA 
  90YES R  ORF81 MAVP-Q gDNA TTACCATATAATACCATGTTCACGAAGTATC  
  VopAYES FRBS  vopA MAVP-Q gDNA GACATGGATGTCGATAGTAAAGCAGGACC 
  VopAYES R  vopA MAVP-Q gDNA AGAGAAGTCACTCACTATTCACACCGCA 
  VopCYES FRBS vopC MAVP-Q gDNA AACATGGTAGAATTAAAGCAAATATTTA 
  VopCYES R  vopC MAVP-Q gDNA CTACGCTAATTTGACTACTTTACTTTG 
  VopLYES FRBS  vopL MAVP-Q gDNA AGACGATGGTTAAGTCAACCTTTA 
  VopLYES R  vopL MAVP-Q gDNA TTAAGACAATTTTGCTGCCA  
  VopZYES FRBS  vopZ - 
VPaIα 
MAVP-C gDNA ATTATGGCTGGGTATACTGATGTAAAACCGT 
  VopZYES R  vopZ - 
VPaIα 
MAVP-C gDNA ATCAAGAACTGTCATGGCTTTCCTCTA 
  VopZYES FRBS  vopZ - 
VPaIγ 
MAVP-Q gDNA ATTATGGCTGGGTATACTGATGTAAAACCGT  
  VopZYES R  vopZ - 
VPaIγ 
MAVP-Q gDNA ATCAAGAACTGTCATGGCTTTCCTCTA 
  VscNYES FRBS  vscN2 MAVP-Q gDNA GTGATGGTACAGCACTATTTTAAGGTCAAGGA 
  VscNYES R  vscN2 MAVP-Q gDNA TATATCAATAAGCTGACCAAATTCTCTCCAT  
          
Competency Plasmid       
  PrSEE34 araC SOE AF araC pSW7848 TGCTCTGCGAGGCTG 
  PrSEE35 araC SOE AR araC pSW7848 TTGACCTCTTTAATCTGAATAACGGGTATGGAGAAACA 
  PrSEE36 tfox SOE BF tfoX MAVP-Q gDNA TGTTTCTCCATACCCGTTATTCAGATTAAAGAGGTCAA 
  PrSEE37 tfoX SOE BR tfoX MAVP-Q gDNA AACGATGACGATTGGACA 
          
   
Genetic Knockouts       
  Puskar's vscN1 AF vscN1 MAVP-26 gDNA ATTTTCTGTTCTATTGCCACC 
  PrSEE10 vscN1-GmAR2 vscN1 MAVP-26 gDNA AGGCGACAAGGTGCTGAATAGAAAGGATGG 










  PrSEE9 VSCN1-GmBF2  GenR 
cassette 
PCR product CCATCCTTTCTATTCAGCACCTTGTCGCCT 
  PrSEE11 VscN1-GmBR2  GenR 
cassette 
PCR product TGGGCACGAGCAAATTGTTAGGTGGCGGTA 
  PrSEE12 VscN1-GmCF2  vscN1 MAVP-26 gDNA TACCGCCACCTAACAATTTGCTCGTGCCCA 
  Puskar's vscN1 CR vscN1 MAVP-26 gDNA CTTTGGTTTTATGGGCTTG 
  PrSEE69 631_vscN2_Erm AF vscN2 MAVP-Q gDNA GAACGCCCGATGAAGT 
  PrSEE71 vscN2_Erm AR vscN2 MAVP-Q gDNA GTTTCCGCCATTCTTTGGTGTCTTGATATGACTCCTT 
  PrSEE72 vscN2_Erm BF ErmR 
cassette 
MAVP-Q gDNA AAGGAGTCATATCAAGACACCAAAGAATGGCGGAAAC 
  PrSEE73 vscN2_Erm BR ErmR 
cassette 
MAVP-Q gDNA AGACAGCCGAACGTACTCCTTTACAAAAGCGACTCATAGA 
  PrSEE74 vscN2_Erm CF vscN2 MAVP-Q gDNA TCTATGAGTCGCTTTTGTAAAGGAGTACGTTCGGCTGTCT 
  PrSEE75 vscN2_Erm CR vscN2 MAVP-Q gDNA TGATACCCAGTCATAATAAATG 
  PrSEE76 32_Erm AF ORF32 MAVP-Q gDNA AGGTATTACTCAAGAAGGACTGT 
  PrSEE77 631 32_Erm AR ORF32 MAVP-Q gDNA GTTTCCGCCATTCTTTGAGTGTTAGTTGTGTTATGTTGTT 








  PrSEE80 631 32_Erm CF ORF32 MAVP-Q gDNA TCTATGAGTCGCTTTTGTAAACAATGTATTCTGAAGTGGAC 
  PrSEE81 631 32_Erm CR ORF32 MAVP-Q gDNA AGACACCAGCACTCACGA 
  ORF34.5SoAF ORF34-35 MAVP-Q gDNA ATAACAACGGTTGATTTAATACTCTT 
  ORF34.5SoAR ORF34-35 MAVP-Q gDNA GTTTCCGCCATTCTTTGCTAACTCTGTTGAATGTAGG 
  ORF34.5SoBF ErmR 
cassette 
pEVS170 CCTACATTCAACAGAGTTAGCAAAGAATGGCGGAAAC 
  ORF34.5SoBR ErmR 
cassette 
pEVS170 GTTCTAACCATAGGACTGATTTACAAAAGCGACTCATAGA 
  ORF34.5SoCF ORF34-35 MAVP-Q gDNA TCTATGAGTCGCTTTTGTAAATCAGTCCTATGGTTAGAAC 
  ORF34.5SoCR ORF34-35 MAVP-Q gDNA ACCTTGCTCCTTAATTTGCCT 
  PrSEE41 ORF85 AF ORF76 MAVP-Q gDNA TGCCATTTACCTGTGACAT 
   
  PrSEE42 ORF85 AR ORF76 MAVP-Q gDNA GTTTCCGCCATTCTTTGACTACGCTAATTTGACTACTT 
  PrSEE43 ORF85 BF ErmR 
cassette 
pEVS170 AAGTAGTCAAATTAGCGTAGTCAAAGAATGGCGGAAAC 
  PrSEE44 ORF85 BR ErmR 
cassette 
pEVS170 TTCGCATCTGATTCAACTTTACAAAAGCGACTCATAGA 
  PrSEE45 ORF85 CF ORF76 MAVP-Q gDNA TCTATGAGTCGCTTTTGTAAAGTTGAATCAGATGCGAA 
  PrSEE46 ORF85 CR ORF76 MAVP-Q gDNA CATACAATGAATACCTCCACA 
  G88SoAF2 ORF81 MAVP-Q gDNA TGCCCATTCAAATACGCT 
  G88SoAR ORF81 MAVP-Q gDNA GTTTCCGCCATTCTTTGTATTAACATTTTTATCCG 
  G88SoBF ErmR 
cassette 
pEVS170 CGGATAAAAATGTTAATACAAAGAATGGCGGAAAC 
  G88SoBR ErmR 
cassette 
pEVS170 GGATGTATTTCGGGTTGTTTACAAAAGCGACTCATAGA 
  G88SoCF ORF81 MAVP-Q gDNA TCTATGAGTCGCTTTTGTAAACAACCCGAAATACATCC 
  G88SoCR2 ORF81 MAVP-Q gDNA GTTATTGACACTGATAGTGGCTT 
  QVopVSoAF vopV MAVP-Q gDNA CGATGACTCCCGATTTCCA 
  QVopVSoAR vopV MAVP-Q gDNA GTTTCCGCCATTCTTTGCTATTTATCATATTAAAACCTCA 
  QVopVSoBF ErmR 
cassette 
pEVS170 TGAGGTTTTAATATGATAAATAGCAAAGAATGGCGGAAAC 
  QVopVSoBR ErmR 
cassette 
pEVS170 CGGAATCTCATAATCAGACTTTACAAAAGCGACTCATAGA 
  QVopVSoCF vopV MAVP-Q gDNA TCTATGAGTCGCTTTTGTAAAGTCTGATTATGAGATTCCG 
  QVopVSCR vopV MAVP-Q gDNA ATCATATAGACTCCAAGACACCTC 
  Q44SoAF vopZ VPaIγ MAVP-Q gDNA AGGAGTACGTTCGGCTGTCT 
  Q44SoAR vopZ VPaIγ MAVP-Q gDNA GTTTCCGCCATTCTTTGATACCCAGTCATAATAAATG 
  Q44SoBF ErmR 
cassette 
pEVS170 CATTTATTATGACTGGGTATCAAAGAATGGCGGAAAC 
  Q44SoBR ErmR 
cassette 
pEVS170 GAAATACTCACCATCGAGTTTTACAAAAGCGACTCATAGA 
  Q44SoCF vopZ VPaIγ MAVP-Q gDNA TCTATGAGTCGCTTTTGTAAAACTCGATGGTGAGTATTTC 
  Q44SoCR vopZ VPaIγ MAVP-Q gDNA AGTGCTAATCCTGTTCAAGTGG 
Erm = erythromycin; Gen = gentamycin 
 
  
Table 2.4: Plasmids used in this study 
Plasmid Description Relevant characteristics Reference 
Competency Plasmid       
  pEVS79 moderate suicide vector in V. parahaemolyticus V. fischeri suicide cloning 
vector, ChlR, TetR 
257 
  pSW7848 pBAD promoter ChlR, R6K γ-ori-based suicide 
vector, ccdB toxin gene under 
the control of an arabinose-
inducible and glucose-
repressible promoter PBAD. 
258 
  pSEE1 competency plasmid, moderate suicide vector in V. 
parahaemolyticus 
ChlR This Study 
 pSEE21 pCR2.1-TOPO: araC-ParaBAD-tfoX  KanR This Study 
          
Genetic Knockouts       
  pBD4 Gen cassette ErmR 259 
  pEVS170 Erm cassette ChlR, mini-Tn5-Erm, oriVR6K 
oriTRP4 KanR 
260 
  pCR2.1-TOPO cloning vector KanR Thermo Fisher 
Scientific 
  pEVS104 helper plasmid for TPM Conjugative plasmid with tra 
and trb genes 
257 
  pSEE2 pCR2.1-TOPO:ST631vscN1::Gen vscN1 gene knockout KanR This Study 
  pSEE3 pEVS79:ST631vscN1::Gen  vscN1 gene knockout on 
moderate suicide vector 
ChlR, GenR This Study 
  pSEE4 pCR2.1-TOPO:ST631vscN2::Erm  ST631 vscN2 knockout ChlR, ErmR This Study 
  pSEE5 pCR2.1-TOPO:ST631ORF32::Erm  ST631 ORF32 knockout ChlR, ErmR This Study 
  pSEE6 pCR2.1-TOPO:ST631ORF34-35::Erm   ST631 
ORF34/ORF35 knockout 
ChlR, ErmR This Study 
  pSEE7 pCR2.1-TOPO:ST631ORF76::Erm   ST631 ORF76 knockout ChlR, ErmR This Study 
  pSEE8 pCR2.1-TOPO:ST631ORF81::Erm   ST631 ORF81 knockout ChlR, ErmR This Study 
  pSEE9 pCR2.1-TOPO:ST631ORFVopV::Erm    ST631 VopV 
knockout 
ChlR, ErmR This Study 
   
  pSEE10 pCR2.1-TOPO:ST631ORFVopZ::Erm ST631 VopZ knockout ChlR, ErmR This Study 
          
Yeast Toxicity Assay       
  pYES2.1-V5-His-
TOPO 
cloning vector GAL1 promoter Thermo Fisher 
Scientific 
  pSEE11 pYES2.1-V5-His-TOPO:ST631ORF32   ST631 ORF32 
expression vector 
GAL1 promoter This Study 
  pSEE12 pYES2.1-V5-His-TOPO:ST631ORF34   ST631 ORF34 
expression vector 
GAL1 promoter This Study 
  pSEE13 pYES2.1-V5-His-TOPO:ST631ORF35   ST631 ORF35 
expression vector 
GAL1 promoter This Study 
  pSEE14 pYES2.1-V5-His-TOPO:ST631ORF76   ST631 ORF76 
expression vector 
GAL1 promoter This Study 
  pSEE15 pYES2.1-V5-His-TOPO:ST631ORF81   ST631 ORF81 
expression vector 
GAL1 promoter This Study 
  pSEE16 pYES2.1-V5-His-TOPO:ST631VopA   ST631 VopA 
expression vector 
GAL1 promoter This Study 
  pSEE17 pYES2.1-V5-His-TOPO:ST631VopC   ST631 VopC 
expression vector 
GAL1 promoter This Study 
  pSEE18 pYES2.1-V5-His-TOPO:ST631VopL   ST631 VopL 
expression vector 
GAL1 promoter This Study 
  pSEE19 pYES2.1-V5-His-TOPO:ST631VopZ   ST631 VopZ 
expression vector 
GAL1 promoter This Study 
  pSEE20 pYES2.1-V5-His-TOPO:ST3VopZ ST3 VopZ expression 
vector 
GAL1 promoter This Study 
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Abstract 
Vibrio parahaemolyticus is an emergent human pathogen that is the primary cause of 
seafood-borne bacterial disease in the United States (US) and worldwide. Cases of V. 
parahaemolyticus infection have increased recently, especially from the North Atlantic Ocean. 
Most V. parahaemolyticus clinical cases harbor one of three evolutionary related, yet distinct 
Vibrio Pathogenicity Islands (VPaIs): VPaIα (tdh+), VPaIβ (trh+), or VPaIγ (tdh+/trh+). Strains 
harboring VPaIα cause the most infections globally, but VPaIγ-harboring strains cause most US 
infections.  Of the different VPaIγ lineages identified thus far, tdh3-VPaIγ is most frequently 
associated with disease whereas tdh5-VPaIγ are more often associated with strains from the 
environment. In this study, we provide evidence that effectors from tdh3-VPaIγ and tdh5-VPaIγ 
are evolutionarily divergent, and variation impacts effector toxicity, which may enhance 
environmental fitness. This work lays the foundation for understanding how the unique 
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environmental and population context of each VPaIγ lineage shaped the evolution of differing 
degrees of toxicity that promote host fitness. 
 
Introduction 
Vibrio parahaemolyticus is an important human pathogen that is the primary cause of 
seafood-borne bacterial infections in the United States and worldwide 10,18,261. V. parahaemolyticus 
populations are diverse, and the majority of strains are harmless to humans 10,18. Human infection 
with V. parahaemolyticus causes inflammatory gastroenteritis through the production of secreted 
toxins encoded by one of three evolutionarily distinct mobile Vibrio Pathogenicity Islands (VPaIs) 
identified as VPaIα, VPaIß, and VPaIγ 65  containing a Type Three Secretion System (T3SS) (see 
Chapter 1 Figure 1.1 and Xu et al. 2017 107) 75,98,105–107. These VPaI each confer production of an 
array of toxins; however, only a few of these toxins are known to contribute to enterotoxicity. 
Though the VPaIs also encode two hemolysin genes, the thermostable direct hemolysin (Tdh) and 
thermostable related hemolysin (Trh), both of which are helpful in identifying presence and 
identity of different VPaIs, neither are key virulence factor for gastric disease 6,8,71–78.  
Populations of V. parahaemolyticus harboring any one of the three VPaI are typically in 
distinct, but non-uniform, geographic locations worldwide. Strains harboring VPaIα (tdh+),  first 
identified as VPaI-7 106 in strain RIMD2210633, and especially pandemic V. parahaemolyticus 
known as Sequence Type (ST) 3 or serovar O3:K6 105, are prevalent in Asia and cause the majority 
of infections globally 105. Besides causing two outbreaks and sporadic infections, ST3 has not 
established long-term populations along the Atlantic coastal areas of North America  
26,45,173,176,178,185–188. The most clinically prevalent STs causing infections in the United States, 
harbor VPaIγ (tdh+/trh+) or less frequently VPaIß (trh+) 19,39,40,65,190. These related VPaI are 
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functionally analogous to but divergent from VPaIα, with limited shared content 65. VPaIγ 
11,65,98,107,109 contains genetic elements from both VPaIα and VPaIß 107, but displays a core content 
orthologous and syntenous with VPaIß 97,107 and shares the same array of predicted T3SS2 
effectors, only some of which are conserved in VPaIα (see Chapter 2 Figure 2.1 and Xu et al. 2017 
107). Thus far, experimental evidence links only three of the eight toxins encoded by VPaIα, VopV, 
VopZ, and most recently VopC, to gastrointestinal disease. Both VPaIß and VPaIγ encode VopC. 
Since the genes that are analogous to the VopV and VopZ toxins are so divergent from the 
characterized toxins in VPaIα, toxins other than VopV and VopZ, conserved between VPaIß and 
VPaIγ, may be critical for disease.  
Historically, V. parahaemolyticus rarely caused infections from sources in the Northeast 
United States; thus, there was a long-held belief that the North Atlantic’s environmental conditions 
did not sustain pathogenic populations 33,44. However, recently, infections associated with North 
Atlantic harvested shellfish have increased. This trend coincided with warmer than usual ocean 
temperatures in the region and the incursion and establishment of non-native lineages from the 
Pacific Northwest and the Gulf of Mexico 8,22,48,49. Non-natives harboring VPaIγ include several 
Pacific derived pathogenic lineages (ST36, ST43, and ST636) 39,40,107, and long-time residents of 
the Gulf of Mexico or Atlantic (ST34, ST110, and ST308) 22,53,60,190,192. However, not all of these 
strains cause human infections, and those that have evolved among the Pacific population are more 
clinically prevalent in the Northeast US, whereas those arising in the Atlantic and Gulf of Mexico 
are less clinically prevalent 11. It is noteworthy that the originating population corresponds more 
strongly with clinical prevalence than even VPaI type, as strains harboring VPaIγ reside in both 
populations, and have invaded the Northwest Atlantic. 
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Of the seven identified tdh alleles, four, including tdh3, tdh5, tdh6, and tdh7, are harbored 
by VPaIγ suggesting the potential that these are distinct VPaI lineages evolving in parallel that, 
due to the mobility of strains and horizontal nature of VPaI movement, are now globally distributed 
(Figure 3.1). VPaIγ that harbor the tdh3 allele predominate among the North Pacific population of 
V. parahaemolyticus (blue population block in Figure 3.1). These most notably include all 
members of the ST36 clonal complex 11 (ST36, ST38, ST39, and ST59) and several unrelated 
lineages isolated in the Pacific, including ST50 and ST636. In contrast, VPaIγs that harbor a tdh5 
allele predominate among the longstanding Gulf of Mexico and the Atlantic Ocean populations 
(red and purple populations in Figure 3.1) including ST34, ST110, and ST674 11,22,107,190,198 . 
Importantly, V. parahaemolyticus harboring tdh3-VPaIγ, even those that acquired this VPaI 
relatively recently (e.g., ST631), are clinically prevalent, whereas no lineage harboring tdh5-VPaIγ 
is clinically prevalent even though they are frequently cultured from the environment 11. Strain 
lineages harboring tdh6- and tdh7-VPaIγ are among several of the global populations, including 
ST308, ST23, ST1123, and ST676 (Figure 3.1), but, notably, very few of these caused repeated 
infections. Specifically ST43, a lineage that likely arose in the Gulf of Mexico (red population in 
Figure 3.1) based on population structure analysis, but that translocated and evolved among the 
tdh3-VPaIγ strains of the Pacific population (blue population in Figure 3.1), harbors the  tdh7-




Figure 3.1: Population origin and global distribution of VPaIs. Global population structure of V. parahaemolyticus from 
whole genomes evaluated in the R statistical package LEA262. tdh alleles harbored on VPaIγ designated below VPaI blocks.  
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 V. parahaemolyticus harboring any of the four VPaIγ types (based on tdh allele) have invaded, 
and some of these are causing infections from US Atlantic coastal waters 11. Furthermore, 
genomics analyses suggest these non-indigenous lineages have donated their VPaIs to the local V. 
parahaemolyticus residents 11. There is a pattern of variation in clinical and environmental 
prevalence in pathogen lineages correlated with the VPaIγ lineage they harbor. Since each VPaIγ 
variant originated from different geographic locations, this suggests a possibility that the 
population in which these VPaIγ variants evolved could  have influenced virulence potential they 
confer 11. Perhaps, then since the T3SS2 toxins confer virulence, perhaps T3SS2 effector variation 
underlies the differences in clinical prevalence.  
Opportunistic pathogens, such as V. parahaemolyticus, evolve in the environment, and the 
"coincidental evolution hypothesis" suggests that maintenance of virulence factors is a response to 
selective environmental pressures instead of for virulence against humans 263. One of the leading 
mortality factors of bacteria in marine and freshwater systems is grazing by phagotrophic protists 
264–267. In response to protozoan predation, virulence mechanisms as defense strategies have 
evolved in bacteria to combat this selective pressure 268. Extracellular pathogens such as V. 
parahaemolyticus, utilize toxin secretion and biofilm formation to avoid internalization by 
protozoan predators and phagocytes 263. Perhaps variation in the novel effectors encoded by VPaIγ 
and linked to population in which the lineages harboring these VPaI evolved might be due to 
differences in environmental conditions such as protozoan predation.  
This study aims to compare the T3SS2 effectors from VPaIγ through analysis of population 
and lineage phylogenetics, assess recombination patterns and effector selection, and utilize 
functional models to elucidate the drivers of the variance in clinical and environmental prevalence 
of these islands in the North Atlantic.  
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Results 
VPaIγ variation arose in geographically distinct populations  
Analysis of the distribution of VPaIs among clinical isolates (2010-2016), updated from work 
in Xu 2017 11, exemplifies that not all VPaIγ-harboring strains are equally prevalent (Table 3.1). 
tdh5-VPaIγ is rare among clinically prevalent strains, but it is in environmental isolates fairly 
commonly.  tdh3-VPaIγ is in two unrelated sequence types (ST36 and ST631) that cause most 
infections in the Northeast United States.  
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Table 3.1: Demographics of Northeast United States pathogenic V. parahaemolyticus. Infections reported in 
four Northeast US States (ME, NH, MA, and CT) between 2010 and 2016, sorted by Vibrio Pathogenicity Island 
(VPaI) and hemolysin content. Note that not all infections were traced to local sources. The environmental 
prevalence of strains harboring VPaIs is based on routine surveillance.  
ST Clinical isolates Environmental Isolates VPaI 
3 2 0 α 
36 91 1 tdh3-γ 
631 24 0 tdh3-γ 
631 1 2 ß 
631 0 1 none 
43 5 0 tdh7-γ 
636 4 0 tdh3-γ 
1127 4 0 ß 
110 3 0 tdh5-γ 
34/324 2 2 tdh5-γ 
674 0 4 tdh5-γ 
674 1 0 none 
308 2 0 tdh6-γ 
12 2 0 ß 
162 2 0 none 
194 2 0 none 
809 2 0 ß 
1716 2 0 ß 
1123 1 1 ß 
8 1 0 ß 
23 1 0 tdh7-γ 
749 1 0 tdh6-γ 
1295 1 0 none 
134 1 0 none 
741 1 0 none 
98 1 0 ß 
1205 1 0 none 
1561 1 0 none 
1717 1 0 none 
1725 1 0 α 
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To understand this relationship between tdh allele and prevalence, we built phylogenetic 
trees of the tdh genes to glean the evolutionary relationships of the different alleles (Figure 3.2A). 
This analysis exemplifies the distinctive phylogenetic signatures of tdh alleles encoded by VPaIγ 
that differ from tdh1 and tdh2 harbored by VPaIα  (Figure 3.2A). Though tdh3 and tdh5 clearly 
represent divergent lineages, tdh6 most recently evolved from a common ancestor with tdh3, 
whereas tdh7 and tdh4 share ancestry with tdh5. Though the phylogenetic signatures of tdh alleles 
could mean that there are four distinct lineages of VPaIγ (Figure 3.2A), when the entire VPaIγ 
sequences are used for constructing phylogenies and compared with the tdh gene phylogenies, 
tdh3-VPaIγ and tdh5-VPaIγ are again phylogenetically distinct. Curiously tdh7-VPaIγ do not form 
a single clade; rather these VPaIγ group with other VPaIγ by population, where the tdh7-VPaIγ 
harbored by Pacific residential ST43 groups most closely with the Pacific dominant tdh3-VPaIγ, 
and the tdh7-VPaIγ harbored by Gulf of Mexico resident strain ST23 groups with the tdh5-VPaIγ, 
also from Atlantic or Gulf of Mexico residential strains  (Figure 3.2B). This pattern of whole island 
phylogenies that differs somewhat from tdh allele phylogenies underscores the evolutionary 
influence of local populations.  
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Figure 3.2A. Unique tdh alleles associate with each VPaIγ lineage; clinical prevalence 
correlates with tdh3-containing VPaIγ whereas environmental prevalence correlates with 
tdh5-containing VPaIγ. Maximum likelihood (ML) phylogenetic tree of tdh alleles from high-
quality genomes on the National Center for Biotechnology Information (NCBI) database. Alleles 
are colored red to indicate those encoded in the pandemic island, VPaIα. tdh alleles prevalent in 
either clinical or environmental isolates from the Northeast United States coastal areas are 
colored green and blue.  
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Figure 3.2B: tdh3-VPaIγ and tdh5-VPaIγ are distinct lineages. Maximum Likelihood (ML) tree 
constructed using the Jukes-Cantor model with 1000 bootstrap resamplings of VPaIβ and VPaIγ 
from select genomes constructed on sequences corresponding to VPaIγ of ST631 strain MAVP-
Q.  
 
Geographic signatures in the patterns of recombination among and between different 
lineages of VPaIγ suggest they evolved differently in different populations 
Xu et al. examined the short-term evolution of the four types of VPaIγ, identified loci with 
convergent variation, and determined island relatedness based on the non-recombining regions 
using the bioinformatics program Gubbins 11,68. This analysis identified that the  Northwest 
Atlantic native V. parahaemolyticus ST631 harbored a tdh3-VPaIγ related to and derived from the 
same population as the "hypervirulent" Pacific-native ST36, and not the tdh5-VPaIγ that is more 
typical of Atlantic or Gulf of Mexico V. parahaemolyticus populations 11. Their results also 
identified patterns of clustered SNPs between the four VPaIγ types 11. Further analysis of this data 
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of either recombination or convergence (Figure 3.3). This could help explain the unresolved 
common ancestry tdh7-VPaIγ that has been blurred by the geographic separation of host strains 
(ST23 and ST43).  
The VPaIß/VPaIγ maximum likelihood (ML)-tree built with all SNPs (Figure 3.2B), or 
built only with non-recombining SNPs (Figure 3.3) indicate the common ancestry of tdh3-VPaIγ, 
regardless of the strain lineage or population (Atlantic or Pacific). However, phylogenies of tdh7-
VPaIγ constructed using variation only in non-recombining regions produced unexpected topology 
differences for strains that evolved in the Pacific compared to those that evolved in the Atlantic. 
Specifically, when variation excluded recombining regions (Figure 3.3) tdh7-VPaIγs branch by 
geographic population in which they evolved, perhaps reflective of localized adaptation tied to 
variation in non-recombining regions. Furthermore, the tdh7-VPaIγ from ST43 that evolved in the 
Pacific displays recombination patterns similar to that of the Pacific-native tdh3-VPaIγ potentially 
resulting from between island recombination. The tdh7-VPaIγ that evolved in the Gulf of Mexico 
displays recombination patterns similar to that of the Gulf of Mexico population tdh5-VPaIγ. 
Interestingly, one of the four novel T3SS2 toxins (see Ch. 2), Open Reading Frame (ORF) 76 
which is nearby the VopC toxin that is linked to gastric disease caused by ST3, is located in a 
region of elevated SNP density in the tdh5-VPaIγ, indicative of recombination within the tdh5-
VPaIγ clade. The first half of a second T3SS toxin, ORF35, is in a recombination region within all 
four VPaIγ clades. 
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Figure 3.3: Geographic signatures of recombining regions of VPaIγ and predicted toxin 
genes constructed with Gubbins. ML phylogeny was built on SNPs identified in non-
recombining regions (non-colored regions) and excluded regions of recombination exhibiting a 
higher SNP density (colored blocks) 68. Red blocks indicate recombination within a clade of related 
isolates, whereas blue blocks indicate recombination with isolates that were absent from the 
analysis. Strains are colored by Sequence Type (ST). “PaI” designation after strain name indicates 
that just the VPaI sequence was used in the analysis. Isolates are colored by sequence type using 
a uniform coloring scheme as in Figure 3.2B and Figure 3.4. 
 
Next, we investigated in more detail whether the phylogeny of putative effectors exhibited 
the same topology as the entire island to evaluate whether the tree topology group the genes by  
their historical lineages or local environments. We compared effector sequences from clinical 
isolates harboring, tdh3-VPaIγ, tdh5-VPaIγ, tdh7-VPaIγ, and VPaIß isolated in the northeast 
United States between 2010 and 2016. ML trees were constructed for each putative effector from 
isolates representing STs and VPaIs that either commonly cause infections or prevail 
environmentally in the Northeast United States (Table 3.1, Figure 3.2B). Effectors from the 
clinically prevalent/environmentally infrequent STs (ST36, ST631 clade II, and ST636) harboring 
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infrequent STs (ST674 and ST34) harboring tdh5-VPaIγ. The divergence between tdh3-VPaIγ and 
tdh5-VPaIγ effector orthologs is most notable in the ORF76 phylogeny. Effectors from tdh6- and 
tdh7-VPaIγs did not show as strong of patterns in their evolutionary relationships like the other 
VPaIγ effectors.  
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A. ORF32        
B. ORF34 
C. ORF35 





Figure 3.4: The e A-E) Maximum-likelihood gene trees of putative effectors ORF32, ORF34, 
ORF35, ORF76, and ORF81. tdh3-VPaIγ: MAVP-Q=ST631 clade II, MAVP-26=ST36, MAVP-
50=ST636, tdh5-VPaIγ strains include CT4291=ST674 and CTVP19C=ST34/324, tdh6/7-VPaIγ 
strains include MAVP67=ST308 and MAVP71=ST43, and VPaIβ strains include 
MAVP25=ST1127, MAVP-R=ST631 clade I. 100 bootstraps were run and bootstrap value shown 
for each branch. The homologs used as outgroups for all five effectors were chosen based on high 
volution of some T3SS2 effectors differs from the evolution of their whole VPaI. 
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sequence identity and 99% query coverage when using the effectors from strain MAVP-Q as a 
query in BLASTn. Outgroup percent sequence identity corresponding to each ORF in MAVP-Q 
for ORF 32/34/35/76/81 were 68.28%, 98.49%, 89.6%, 86.03%, and 68.28% respectively.  
 
tdh3-VPaIγ and tdh5-VPaIγ are very similar in structure, with a few striking differences 
(Figure 3.5). tdh5-VPaIγ (from strain CT4291) contains ten more ORFs than tdh3-VPaIγ (from 
strain MAVP-Q), and several of these additional genes encode RTX toxin components that are 
conserved in VPaIβ (data not shown) suggesting they were potentially lost from tdh3-VPaIγ. 
Homologous effectors are slightly divergent, as indicated by a decreased BLASTn percent identity. 
In the gene map, regions that flank ORF76 are divergent, and these regions correspond to areas 
identified by the prior analysis as having undergone recombination in tdh5-VPaIγ lineages. 
 
Figure 3.5. Comparison of content and conservation in tdh3-VPaIγ and tdh5-VPaIγ. 
Candidate effectors (including divergent vopV and vopZ homologs) are colored red. Arrows 
designate open reading frames. Grey bars indicate the percent similarity between homologs. tdh3-
VPaIγ representative strain MAVP-Q (MF066646). tdh5-VPaIγ representative strain CT4291 
(SRX7416425).  
 
VPaIγ effector orthologs contain amino acid variation 
Next, we compared the effectors’ amino acid composition to examine whether the 
nucleotide divergence between VPaIγ effectors led to nonsynonymous mutations that could impact 
effector function. Alignments of effectors used to construct the ML trees in Figure 3.4, were 
61 
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translated and color-coded by amino acid grouping to aid in the visualization of differences (Figure 
3.6) 269. After collapsing the conserved sites, the effectors contained unequal percentages of 
variable amino acid sites. The percentage of variable amino acid sites in ORF32, ORF35, ORF76, 
and ORF81 was 15.9%, 4.4%, 16.6%, and 10.8% respectively. Due to the deletions and/or 
duplications and the repetitive nature of the ORF34 sequence that makes alignment difficult, the 
percentage of variable amino acid sites was not calculated for ORF34.  
A direct comparison of the effectors’ amino acid composition from the tdh3-VPaIγ and 
tdh5-VPaIγ revealed three of the novel effectors, ORFs 32/76/81, differ in amino acid composition 
in their N-terminal region. This region of T3SS effectors contain structural patterns that include a 
targeting signal in the first ~15-30 amino acid residues, an optional chaperone binding domain in 
the following ~50-150 amino acids, and the remaining protein generally consists of effector 
binding domains. ORF76 has a dramatic change in the N-terminal region, with a cysteine at 
position 15 in tdh5-VPaIγ and a bulky tyrosine in tdh3-VPaIγ. This results not only in different 
size residues but also potentially alters the formation of a disulfide bridge. There is no recognizable 
universal secretion signal of T3SS effectors, and thus advanced machine learning approaches are 
necessary to predict these effectors 202,207,208,270–272. Despite the amino acid alterations in protein’s 
secretion signal region, we cannot determine if these changes alter secretion. The amino acid 
composition of the chaperone binding and effector domain regions of all five effectors differed 
between tdh3-VPaIγ and tdh5-VPaIγ. Notably, ORF34 orthologs from tdh3-VPaIγ and tdh5-VPaIγ 
contained two amino acid differences in the effector domain region, by lineage, that could alter 
each protein structure. The two orthologs have amino acid residues, either isoleucine or a tyrosine, 
that vary in size at position 1348. At position 1412 in the protein, the two orthologs have either a 
negatively charged glutamic acid residue or a positively charged lysine residue. These dramatic 
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changes suggest that protein structure would change, thus potentially altering function. However, 
since there is no data on the function of these effectors, we cannot predict how these changes 




Figure 3.6: Variable amino acid composition associated with VPaIγ lineage. tdh5-VPaIγ strains include CT4291=ST674 and 
CTVP19C=ST34/324, VPaIβ strains include MAVP25=ST1127, MAVP-R=ST631 clade I, tdh6/7-VPaIγ strains include 
MAVP67=ST308 and MAVP71=ST43, and tdh3-VPaIγ MAVP-Q=ST631 clade II, MAVP-26=ST36, MAVP-50=ST636. 
Amino Acid coloring scheme: blue = positively charged, red = negatively charged, green = polar uncharged, light yellow = 
hydrophobic, yellow = proline/tyrosine, orange = cysteine, purple = glycine.  
Island ST Strain 1 5 6 11 12 13 14 21 23 24 25 36 40 41 53 54 65 77 82 97 99 101 103 117 128 152 153 160 165 166 174 197 198 209 218 222 223 224 232 242 243 264 271 279 284 290
VPaIß 1127 MAVP-25 ? L T Q N F I D G D N S K P L G L A D R H E K E E G V D F E N L V N A K E K N V L T T T M *
VPaIß 631 CI MAVP-R M L T Q N F I D G D N S K P L G V A D R H E K E K G V D V E K P V N T K E K N V L T T T M *
tdh 5-VPaIγ 674 CT4291 M L T Q H N I N S E S S N T F A L T N S N D N D K G V E V K K P A N A K G K S I S I A D L ?
tdh 5-VPaIγ 34/324 CTVP19C M L T Q H N I N S E S S N T F A L T N S N D N D K G V E V K K P A N A K G K S I S I A D L ?
tdh 6-VPaIγ 43 MAVP-71 M I N K H N T N S E N N K T F G L T N R N D N E K G V E V K K P A N A R G R S I S I A D L ?
tdh 3-VPaIγ 636 MAVP-50 M L T Q H N T N S E N N K T F G L T N R N D K E K - - D V E K P V S A K E K N V L T T T M *
tdh 3-VPaIγ 36 MAVP-26 M L T Q H N T N S E N N K T F G L T N R N D K E K - - D V E K P V S A K E K N V L T T T M *
tdh 3-VPaIγ 631 CII MAVP-Q M L T Q H N T N S E N N K T F G L T N R N D K E K - - D V E K P V S A K E K N V L T T T M *
Island ST Strain 12 24 31 32 33 34 35 36 37 38 39 40 89 157 348 588 655 730 863 889 915 1047 1166 1311 1348 1382 1412
VPaIß 1127 MAVP-25 F F - - - V P E ? - - ? S V R T S G V V I L I S I F E
VPaIß 631 CI MAVP-R F I I P E V P E ? - - ? S V R T S G V L I L I S T Y E
tdh 5-VPaIγ 308 MAVP-67 L F V P E ? - - - - - ? A V R R G G M V I P T N I Y E
tdh 5-VPaIγ 43 MAVP-71 F F V P E V P E ? - - ? A I R R G S M V I P T S I Y E
tdh 6-VPaIγ 674 CT4291 L F V P E V P E ? - - ? A V R R D G M V I P T N I Y E
tdh 6-VPaIγ 34/324 CTVP19C L F V P E V P E V P E V A V R R D G M V I P T N I Y E
tdh 3-VPaIγ 636 MAVP-50 L F I P E ? - - - - - ? A V R R G G M V V P T S T Y K
tdh 3-VPaIγ 36 MAVP-26 L F I P E ? - - - - - ? A V R R G D M V V P T S T Y K
tdh 3-VPaIγ 631 CII MAVP-Q L F I P E ? - - - - - ? A V K R G G M V V P T S T Y K
Island ST Strain 11 18 60 91 119 129 218 226 237
VPaIß 1127 MAVP-25 P Q L E A G N S T
VPaIß 631 CI MAVP-R H Q L E A G N A S
tdh 5-VPaIγ 674 CT4291 P P L E S D N S S
tdh 5-VPaIγ 34/324 CTVP19C P P L E S D N S S
tdh 6-VPaIγ 308 MAVP-67 P P F E A D S S S
tdh 6-VPaIγ 43 MAVP-71 P P L E V G N S S
tdh 3-VPaIγ 636 MAVP-50 P P F Q A D N S S
tdh 3-VPaIγ 36 MAVP-26 P P F Q A D N S S
tdh 3-VPaIγ 631 CII MAVP-Q P P F Q A D N S S
Island ST Strain 8 10 12 15 16 17 18 20 22 24 25 29 32 33 38 45 54 56 65 90 105 137 144 146 152 159 160 164 165 169 170 177 190 194 198 199 217 227
VPaIß 1127 MAVP-25 P Q S Y S G K H E A A R S H K K D D H L G D S A G I A K M A A V A K A M T E
VPaIß 631 CI MAVP-R P Q S Y S G K H E A A R S H R K D D H L G D S A G I A K M A A V A K A M T E
tdh 5-VPaIγ 674 CT4291 S N G C N H K N E T T I S H K Q G N H V G E I S R I A E I A S I E N V L M K
tdh 5-VPaIγ 34/324 CTVP19C S N G C N H K N E T T I S H K Q G N H V G E I S R I A E I A S I E N V L M K
tdh 6-VPaIγ 308 MAVP-67 P Q S Y S G Q H E A A R F N K T D N H L G D S A G L T K M T S I A K A M T K
tdh 6-VPaIγ 43 MAVP-71 P Q S Y S G K H A A A R F N K T D N H L E D S A G L T K M A S I A K A M T K
tdh 3-VPaIγ 636 MAVP-50 P Q S Y S G K H A A A R F N K T D N Y L G D S A G L T K M A S I A K A M T K
tdh 3-VPaIγ 36 MAVP-26 P Q S Y S G K H A A A R F N K T D N Y L G D S A G L T K M A S I A K A M T K
tdh 3-VPaIγ 631 CII MAVP-Q P Q S Y S G K H A A A R F N K T D N Y L G D S A G L T K M A S I A K A M T K
Island ST Strain 6 7 13 33 43 44 51 53 54 59 69 74 88 105 128 138 151 163 171 203 227 244 251 266 288 331
VPaIß 1127 MAVP-25 K K N L K N I K L S S V I L S T A N N E D T T V S V
VPaIß 631 CI MAVP-R K K N L R N V T L L S A I L S T A N N E D T T V S V
tdh 5-VPaIγ 674 CT4291 Q K N I K S I K F L I V T H T T T T D E G A M A S L
tdh 5-VPaIγ 34/324 CTVP19C Q K N I K S I K F L I V T H T T T T D E G A M A S L
tdh 6-VPaIγ 308 MAVP-67 Q K Y L K N I K L L S V T H T T A T D E D T T V N V
tdh 6-VPaIγ 43 MAVP-71 Q K Y L K N I K L L S V T H T T A T D E D T T V N V
tdh 3-VPaIγ 636 MAVP-50 Q R Y L K N I K L L S V T H T A A T D K D T T V N V
tdh 3-VPaIγ 36 MAVP-26 Q R Y L K N I K L L S V T H T A A T D K D T T V N V













When comparing just the effector amino acid composition of tdh3-VPaIγ and tdh5-VPaIγ 
effector orthologs, ORF32 and ORF76 have the lowest percent amino acid similarity at 94.8% and 
89.9%, respectively. In contrast, ORF34 and ORF35 orthologs are more highly conserved, with 
amino acid identity at 99.3% and 99.2% (Table 3.2).  
 
Table 3.2: VPaIγ gene variation. BLASTx percent sequence identity between tdh5-VPaIγ strain 
CT4291 and tdh3-VPaIγ strain MAVP-Q. 









VopV analog 96.2 (146 partial hits) 
VopZ analog 95.5 
 
tdh5-VPaIγ-harboring V. parahaemolyticus require T3SS2 effectors for survival against 
amoeba predation.  
Since tdh3-VPaIγ and tdh5-VPaIγ confer reciprocal patterns of clinical and environmental 
prevalence, we next examined whether T3SS2 secretion of effectors promote environmental 
fitness. We hypothesize that  differences in the effectors could have resulted from environmental 
selection of predation, and in so doing deter protist grazing. We analyzed the growth of V. 
parahaemolyticus strains in the presence of the amoeba predator Acanthamoeba castellanii 273 to 
test whether the T3SS toxins secreted by tdh3-VPaIγ and tdh5-VPaIγ deters protist grazing (Figure 
3.7). Loss of T3SS1 and T3SS2 effectors secretion did not alter survival under grazing pressure 
for V. parahaemolyticus harboring tdh3-VPaIγ. Conversely, loss of the T3SS effector secretion in 
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V. parahaemolyticus strains harboring tdh5-VPaIγ did impair survival under grazing pressure from 
A. castellanii.  
 
 
Figure 3.7: tdh5-VPaIγ T3SS effectors protect against protozoan predation. 10-fold dilutions 
of V. parahaemolyticus were co-cultured with amoeba predator A. castellanii and grown on LB 
agar. 
 
T3SS effectors from tdh3-VPaIγ promote killing of Galleria mellonella 
Next, we used the well-established virulence model, Galleria mellonella, to assess the 
relative contribution of T3SS2 effectors from tdh3-VPaIγ and tdh5-VPaIγ to pathogenesis.  Larvae 
of the greater wax moth G. mellonella have been used as an infection model since 1987 274 because 
they provide a useful insight into the pathogenesis of a wide range of microbial infections, 
including fungal and bacterial pathogens 275. Similar to mammals, insects such as G. mellonella 
possess a complex innate immune system that can provide relevant information towards the 
mammalian infection process 275. In this study, G. mellonella were challenged with V. 
parahaemolyticus strains with and without functional T3SSs to assess the pathogenicity 
contributed by each system (Figure 3.8).  
ΔvscN1 ΔvscN2   
ΔvscN1 
wt 
ΔvscN1 ΔvscN2   
ΔvscN1 
wt 
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Post-infection, G. mellonella were assigned a Health Index score as reported in Loh et al. 
276,277 based on survival, activity, cocoon formation, and melanization. G. mellonella had similar 
health index scores post-infection with wild type tdh3-VPaIγ and tdh5-VPaIγ harboring strains. 
Elimination of secretion by the ancestral and conserved T3SS1 (∆vscN1) ameliorated larvae 
damage by an environmentally prevalent tdh5-VPaIγ strain (ST674 strain, CT4291) to similar 
levels of PBS buffer injection control. Although elimination of T3SS1 (∆vscN1) qualitatively 
ameliorated larval damage by a clinically prevalent tdh3-VPaIγ strain (ST631 strain MAVP-Q), it 
did not do so significantly, likely due to substantial intra-animal variability in response to injection 
with the wild type. Additionally, eliminating the T3SS2 (∆vscN2) system’s function from the 
T3SS1 mutants (a T3SS1/T3SS2 (∆vscN1/∆vscN2) double mutant) did not significantly increase 
larval health by either strain compared to the single T3SS1 (∆vscN1) mutant. But, importantly, 
level or larval damage by the tdh3-VPaIγ-harboring T3SS1/T3SS2 (∆vscN1/∆vscN2) double 
mutant was significantly different  from levels of damage achieved by wild type bacteria. 
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Figure 3.8: V. parahaemolyticus kills Galleria mellonella using a T3SS. Health index score of 
G. mellonella following infection with V. parahaemolyticus strains harboring tdh3-VPaIγ and 
tdh5-VPaIγ, and corresponding TTSS1 and T3SS2 mutants after infection for 24 hours. A higher 
health index rating indicates better health of G. mellonella post-infection. * = p <0.05 each pair 
Student’s t for pair-wise comparisons. 
 
VPaIγ effectors confer differential toxicity towards eukaryotic cells  
To evaluate each effector’s impact on conserved eukaryotic processes, we used a 
heterologous expression system for T3SS effector toxicity in Saccharomyces cerevisiae. The 
proteins were expressed under the control of a galactose-inducible promoter to determine if their 
toxicity impaired yeast growth. When yeasts expressed ORF34 from tdh3-VPaIγ or tdh5-VPaIγ 
under inducing conditions, they grew nearly as well as they did when grown under the same 
conditions with control empty vector, suggesting neither ortholog was individually toxic (Figure 
3.9A). In contrast, both tdh3-VPaIγ and tdh5-VPaIγ ORF35 orthologs impaired yeast growth. 
Additionally, tdh3-VPaIγ and tdh5-VPaIγ effector orthologs for ORF32, ORF76, and ORF81 
ΔvscN1   ΔvscN1 
ΔvscN2   
ΔvscN1   ΔvscN1 
ΔvscN2   
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impaired growth to differing degrees, based on visual assessment. Yeast harboring ORF32 from 
tdh3-VPaIγ grew the same under both inducing and non-inducing conditions. ORF32 from tdh5-
VPaIγ expression reduced yeast growth substantially. While both ORF76 and ORF81 from tdh3-
VPaIγ reduced yeast growth more than the orthologous ORFs from tdh5-VPaIγ, only ORF81-
induced growth reduction in yeast was significant (Figure 3.9B). In congruence with previous 




Figure 3.9: Orthologous effectors from tdh3-VPaIγ and tdh5-VPaIγ lineages exhibit differences in toxicity towards yeast. 
A) Four-fold dilutions of yeast transformed with pYES2.1:toxin (from tdh3-VPaIγ of ST631 clade II and tdh5-VPaIγ ST674) 
were grown under non-inducing (glucose) and inducing (galactose) conditions. B) Toxicity toward yeast was measured by 
growth on agar plates. CFU/mL was estimated from colony growth under non-inducing and inducing conditions and reported as 





T3SS2 effectors from tdh3-VPaIγ and tdh5-VPaIγ differ in the cytotoxicity of human colon 
cells.  
Next, to compare the degree to which tdh3-VPaIγ and tdh5-VPaIγ effector orthologs were 
involved in T3SS2 dependent cytotoxicity against human colon cells, we co-cultured effector 
deletion mutants of V. parahaemolyticus strains with cultured Caco-2 colorectal tumor cells. The 
strain’s cytotoxicity was evaluated by the release of cytosolic lactate dehydrogenase (LDH) from 
Caco-2 cells (Figure 3.10). Because the effectors secreted by the ancestral T3SS1 of V. 
parahaemolyticus do not contribute to enterotoxicity during infection but are cytotoxic to cultured 
human colon cells, we eliminated the secretion of T3SS1 effectors by deleting the T3SS1 ATPase 
(vscN1) prior to generating individual T3SS2 effector knockouts. Therefore, all strains other than 
the wild type carry a ΔvscN1 mutation.  
V. parahaemolyticus strains harboring T3SS1 were cytotoxic towards Caco-2 cells, 
regardless of which VPaI they carried (tdh3-VPaIγ or tdh5-VPaIγ) with tdh5-VPaIγ strain causing 
slightly less cell damage. This similar cytotoxicity is likely due to the presence of the ancestral 
T3SS1. When this system is removed, the strain harboring tdh3-VPaIγ was more cytotoxic than 
the strain harboring tdh5-VPaIγ. Since Caco-2 cytotoxicity assays are a proxy for V. 
parahaemolyticus virulence, this result agrees with our expectation that the more clinically 
prevalent strains harboring tdh3-VPaIγ are more toxic than strains harboring tdh5-VPaIγ.  
Next, we evaluated the contribution of T3SS2 and its effectors to cytotoxicity by T3SS2. 
Deleting the accessory T3SSs ATPases (ΔvscN2) in tdh3-VPaIγ and tdh5-VPaIγ harboring strains 
reduced cytotoxicity towards Caco-2 cells to similar levels. Deleting ORF32 from tdh3-VPaIγ did 
not reduce the cytotoxicity of V. parahaemolyticus, whereas knocking out ORF32 from tdh5-
VPaIγ dramatically reduced its cytotoxicity. ORFs 34 and 35 are likely co-transcribed and thus 
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were deleted together, and designated ORF34-35. The ΔORF34-35 mutation reduced cytotoxicity 
of the tdh3-VPaIγ significantly more than the same mutation in the tdh5-VPaIγ strain. ΔORF76 
and ΔORF81 homolog deletions also followed a similar pattern of cytotoxicity as ΔORF34-5, but 
only the ΔORF81 derivatives significantly differed from each other. The analogs to the VPaIα 
primary effectors VopV and VopZ were also deleted in VPaIγ strains and assessed for cytotoxicity. 
Though divergent, the tdh3-VPaIγ VopV and VopZ homologs are cytotoxic.  
 
Figure 3.10. Reduced cytotoxicity towards Caco-2 cells mirrors the difference in toxicity 
towards yeast. The human colorectal cancer cell line, Caco-2 cells, were co-incubated with V. 
parahaemolyticus strains defective in T3SS1 and harboring indicated ORF deletions. We predict 
ORFs 34 and 35 are co-transcribed and thus deleted both simultaneously. Percent cytotoxicity, 
estimated by the quantity of lactate dehydrogenase (LDH) in the well after co-culture, was 
calculated by the following equation: [optical density at 490 nm (OD490) of experimental release - 
OD490 of spontaneous release]/(OD490 of maximum release - OD490 of spontaneous release)*100%. 
Spontaneous release is the amount of LDH released from the cytoplasm of uninfected cells. The 
maximum release is the total amount of LDH released after the complete lysis of uninfected cells. 
* = p <0.001 Tukey Kramer HSD for pair-wise comparisons. Data represents the mean ± standard 
deviation from one experiment using five individual bacterial colonies per strain, performed in 
triplicate. The experiment was repeated twice with similar results 
 
ΔvopZ 
ΔvscN1   
ΔORF34-35 
ΔvscN1   
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Discussion 
The continuous global spread of V. parahaemolyticus has led to population mixing and 
horizontal gene transfer of VPaIs 11,22,26,48,197. The pathogenicity island’s additional genetic content 
expands the flexible gene pool and may enhance fitness under specific environmental conditions 
278. For example, toxins secreted by the T3SS2 on VPaIα enhance V. parahaemolyticus persistence 
while in the presence of bacterivorous protists 273 and enable growth and invasion in mammalian 
gastrointestinal tract 139,141,147. Here we provide evidence that strains with different VPaIγ lineages 
recently spread into the North Atlantic population 11,22,197 contain evolutionary divergent toxins 
that may provide a fitness benefit. The blocks of homoplasy in the VPaIγ lineages likely indicate 
recombination in each of the geographic populations. This is exemplified by tdh6-VPaIγs 
containing different recombination regions that correlate with the population they evolved with. 
The Pacific-evolving tdh7-VPaIγ has blocks of recombination similar to that of the fellow Pacific-
evolving tdh3-VPaIγ clade, and the Gulf of Mexico-evolving tdh7-VPaIγ has some blocks of 
recombination similar to that of the fellow Gulf of Mexico-evolving tdh5-VPaIγ clade. This 
recombination pattern indicates that the surrounding population is a major contributor to the 
content of these VPaIs. This pattern could have arisen by an ancestor VPaIγ-harboring strain that 
began evolving with their local areas during global spread. Continued analysis of these populations 
that recently relocated to the Northwest Atlantic will demonstrate local population’s role in 
shaping the evolution of these islands.  
In the North Atlantic, tdh3-VPaIγ containing strains are clinically prevalent and 
environmentally infrequent, while the reciprocal pattern occurs with tdh5-VPaIγ containing strains 
11. This reciprocal clinical/environmental relationship between tdh3-VPaIγ and tdh5-VPaIγ 
containing strains suggests that variation in gene content between the islands could promote 
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infection or environmental success, respectively. Since geographic signatures in the patterns of 
recombination differ between the Pacific and the Gulf of Mexico/Atlantic evolving populations, 
we evaluated whether the toxins from the tdh3-VPaIγ and tdh5-VPaIγ lineages originating out of 
these regions contribute to the VPaIs’ reciprocal environmental and clinical prevalence in the 
North Atlantic. We assessed the contribution of the tdh3-VPaIγ and tdh5-VPaIγ towards clinical 
and environmental success using three functional models systems: G. mellonella infection 279, 
human colon cell culture cytotoxicity 9, and A. castellanii predation 280.  
During infection, V. parahaemolyticus faces defenses from the human innate immune 
system. To assess whether the effectors secreted by the accessory T3SS on VPaIγ promote 
successful invasion, we challenged G. mellonella with V. parahaemolyticus. The G. mellonella 
infection model has been used to assess bacterial virulence against innate immune defenses for 
many gram-negative pathogens 277 such as Pseudomonas aeruginosa 281, Escherichia coli 282, 
Legionella pneumophila 283, and  Klebsiella pneumonia 284. The insect innate immune system is 
complex and mirrors responses seen in mammals such as cellular response, humoral response, and 
antibacterial peptide production 285,286. Our results suggest that the T3SS effectors from tdh3-
VPaIγ contribute towards the successful invasion of V. parahaemolyticus by overcoming innate 
immune system defenses 275,277. This response displays the virulence fitness benefit conferred by 
the presence of VPaIγ in V. parahaemolyticus.  
V. parahaemolyticus colonizes primarily the distal small intestine during infection, where 
it forms microcolonies and induces substantial epithelial damage 125,135,137,138.  In this study the 
Caco-2 were representative of differentiated enterocytes that occur in the small intestine 245, 
previously shown as an effective proxy for evaluating gastric pathogen virulence 124,141,165. We 
identified which T3SS effectors promoted V. parahaemolyticus virulence, without other 
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confounding variables such as mucus, microbiota, and the innate immune system 245. Co-culture 
of Caco-2 cells with tdh3-VPaIγ and tdh5-VPaIγ harboring strains of V. parahaemolyticus indicate 
that the tdh3-VPaIγ T3SS2 effectors are greater contributors to the cytotoxicity of these human 
colon cells than those from tdh5-VPaIγ.  
 Like other opportunistic pathogens such as P. aeruginosa 287, V. parahaemolyticus evolves 
in the environment where toxin secretion is an important defense tactic against protozoan predation 
263,288. Protozoan predators are considered the “training grounds” for bacterial pathogens, allowing 
refinement of defense tactics, which are coincidentally beneficial to pathogenesis in humans 
263,289,290. V. parahaemolyticus is a member of the marine community 33,291,292  and thus commonly 
interacts with protozoan predators 273,293. The T3SS effectors on VPaIα promote survival of V. 
parahaemolyticus against diverse protist predators 273, similarly to the protective effects shown by 
T3SS effectors from tdh5-VPaIγ against the predation pressure from A. castellanii. Intriguingly, 
the tdh3-VPaIγ-harboring strain was not affected by A. castellanii predation. To be a significant 
human pathogen, V. parahaemolyticus needs to survive in the environment and grow to high 
enough concentrations to be ingested by humans, perhaps these V. parahaemolyticus lineages have 
a mechanism outside of the VPaIγ that allows for increased environmental survival.  
Our findings suggest that the difference between the clinical prevalence of tdh3-VPaIγ and 
tdh5-VPaIγ may in part be attributed to their T3SS effectors. To determine which effectors may 
underlie potential differences in virulence, we utilized a bioinformatic and experimental approach 
to compare the effectors in these islands and assess their virulence contribution. Three of the five 
effectors, ORFs 34/35/81 were not in blocks of homoplasy, most likely indicating that they were 
either not in recombining regions or convergence was not occurring on these loci. It appears that 
ORF35 could be undergoing convergence. Convergence at this loci could be supported since 
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ORF35 had the shortest branch lengths of all ortholog phylogenies and had the lowest percentage 
of variable amino acid content between all orthologs examined. The most divergent lineages of 
ORF35, tdh3-VPaIγ and tdh5-VPaIγ, still maintain 99.336% sequence identity at the nucleotide 
level, suggesting maintenance at this locus is important, likely indicting positive selection 294. Two 
of the five toxins, ORF76 and the first half of ORF32, were in blocks of recombination. The 
presence of ORF76 in this region is indicative of recombination at this loci within the tdh5-VPaIγ 
clade. ORF76 orthologs contain the highest percentage of variable amino acid content of all five 
T3SS effectors, and they have the most substantial divergence in the ortholog phylogeny between 
tdh3-VPaIγ and tdh5-VPaIγ as indicated by the longest branch lengths. ORF32 is in a region of 
recombination within all four VPaIγ lineages, and this recombination shines through in its high 
percentage of variable amino acid content between the ORF32 orthologs. The ortholog 
phylogenies of all five toxins show substantial divergence between the tdh3-VPaIγ and tdh5-VPaIγ 
toxin sequences. The modifications in toxins may contribute to their effectiveness in conferring 
pathogenesis or environmental fitness.  
In comparing just effector amino acid composition from tdh3-VPaIγ and tdh5-VPaIγ 
orthologs, there are major amino acid changes between the two islands in both the chaperone 
binding and effector domain regions of all orthologs, though the way in which these novel effectors 
function is not yet known. Even so, these changes could alter virulence if the chaperone cannot 
bind as effectively, or the functional domains are not working as well. One of the most interesting 
differences is two amino acid changes in the M60-like domain of ORF34. This domain typically 
possesses mucinase activity, which could be beneficial in breaking down the protective mucin 
layer produced by enterocytes to allow for better bacterial adhesion 224,227,295,296. This domain is 
conserved in both pathogenic and commensal bacteria in Proteobacteria, Firmicutes, and 
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Bacteroidetes 224,295. For example, the Enterotoxigenic Escherichia coli (ETEC) effector Yghl, also 
contains an M60-like protease domain, which degrades mucus proteins in mouse small intestine 
epithelium 227,296. The two changes that could affect the protein structure are a size change at 
position 1348 from isoleucine to tyrosine, and a side chain charge switch at position 1412 from a 
negatively charged glutamic acid to a positively charged lysine. Three of the predicted effectors, 
ORFs 32/76/81, have a possible amino acid change in their N-terminal secretion signal region. 
Changes in sequence here could mistarget an effector, causing less secretion, and thus less 
biological effect on its target. ORF76 has a dramatic change in the N-terminal region, with a 
cysteine at position 15 in tdh5-VPaIγ and a bulky tyrosine in tdh3-VPaIγ. There is a size difference 
between these residues, and the possible formation of a disulfide bridge can dramatically alter the 
protein structure. Nonsynonymous substitutions can affect numerous protein features such as 
expression, folding, and binding affinity, which in turn may influence fitness 297–299. Amino acid 
changes seen in these toxins may in part influence the clinical prevalence of strains harboring these 
VPaIγs.  
Finally, to begin efforts to elucidate each effector’s function, we utilized growth inhibition 
phenotyping of yeast expressing the toxins from tdh3-VPaIγ and tdh5-VPaIγ.  This yeast growth 
inhibition model assesses if a protein negatively affects conserved eukaryotic processes such as 
those associated with the cytoskeleton, Rho G and MAPK signaling pathways, apoptosis, and 
vesicle trafficking 233,235. Of the surveyed effectors, only ORF32 and ORF81 homologs varied 
significantly in their toxicity towards yeast, mirroring the results from human colon cell infection. 
The tdh5-VPaIγ ORF32 was significantly more toxic towards yeast than its homolog from tdh3-
VPaIγ. Since V. parahaemolyticus evolves in the environment, we hypothesize that the ORF32 
ortholog in tdh5-VPaIγ has best evolved for survival against eukaryotic predators in the 
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environment, and Caco-2 cells happen to be susceptible as well. Perhaps ORF32 is the T3SS 
effector from tdh5-VPaIγ that promoted survival under grazing pressure from A. castellanii. Our 
results could follow the coincidental evolution hypothesis, which suggests that bacterial virulence 
factors arise as a protective trait due to the selective pressure of bacterial-protozoan interactions, 
and their virulence in humans is an added benefit 263,300. T3SS effectors on VPaIα have shown to 
promote survival in the presence of predatory protists 273. In the yeast model, both ORF34 
homologs had almost identical levels of minor growth reduction, and both ORF35 homologs both 
killed yeast equally well. When knocked out together, their combined effect truly parses out the 
difference between tdh3-VPaIγ and tdh5-VPaIγ homologs. The tdh3-VPaIγ ΔORF34-35 strain 
showed significantly more reduction in cytotoxicity than tdh5-VPaIγ ΔORF34-35, indicating that 
the structural differences between these two genes may affect infection success. ORF76 and 
ORF81 from tdh3-VPaIγ both might contribute to this island’s clinical prevalence since they are 
more toxic to yeast and are more cytotoxic to human colon cells than their tdh5-VPaIγ homologs. 
Even though further studies are needed to assess each effector’s contribution to gastric infection 
138,139,301, we can see preliminary patterns of toxicity associated with prevalence.  
All four VPaIγ lineages contain recombination patterns indicative of population-based 
evolution. Our study infers that the T3SS effector variation between tdh3-VPaIγ and tdh5-VPaIγ 
could in part contribute to the clinical prevalence of strains harboring tdh3-VPaIγ and 
environmental prevalence of strains harboring tdh5-VPaIγ. However further studies are needed to 
evaluate the impact these effectors have on V. parahaemolyticus fitness. Based on our preliminary 
results, we believe that the variation in ORFs 34/35, ORF76, and ORF81 between tdh3-VPaIγ and 
tdh5-VPaIγ orthologs could contribute to the tdh3-VPaIγ clinical prevalence. With all four VPaIγ 
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lineages now present and mixing in the North Atlantic, it will be interesting to see how these 
islands change over the next decade.   
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Materials and Methods 
Bacterial, Yeast, and Protist Strains and Culture Conditions 
The bacterial strains and plasmids used in this study are described in Table 2.2 and Table 2.3, 
respectively. V. parahaemolyticus was routinely grown at 37°C in Luria-Bertani medium 
supplemented with 2% NaCl (LBS) 251 or in defined minimal media 252 supplemented with 
0.0058% K2HPO4, 0.1% NH4Cl, 0.01mM FeSO4, 0.1 mM Tris pH 7.4, 0.6% glycerol, 1x Artificial 
Sea Water, 0.625µg/mL chloramphenicol, and tap water for trace minerals for transformation.  E. 
coli strains were grown at 37°C in Luria-Bertani medium (LB) as previously described 251. 
Antibiotics were supplemented for selection of mutations and plasmids at the following 
concentrations for V. parahaemolyticus: 12 µg/ml gentamicin (Gen), 2.5 µg/ml chloramphenicol 
(Chl), and 5 µg/ml erythromycin (Erm) and at the following concentrations for E. coli: 50 µg/ml 
kanamycin (Kan), 100 µg/ml ampicillin (Amp), and 25 µg/ml chloramphenicol (Chl).  
S. cerevisiae BY4742 (obtained from Clyde Denis, 253) was maintained in Yeast extract (1%)-
peptone (2%)-and dextrose (2%) medium (YPD)253. Yeast were grown on Synthetic Complete 
Minimal Media (SC-MM) made with Yeast Synthetic Drop-out Medium Supplements without 
uracil (Sigma-Aldrich), supplemented with glucose at 2% once transformed with pYES2.1/V5-
His-TOPO®. S. cerevisiae was grown at 28°C.  
A. castellanii was routinely maintained in proteose peptone, yeast extract, and glucose (PYG) 
medium (ATCC 712 PYG). A. castellanii were maintained by subculturing 4.2% culture into fresh 
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Bioinformatic Analyses 
To investigate the phylogeny of VPaI elements, the sequences of pathogenicity islands were 
extracted from assembled draft genomes using as a reference the island sequences of MAVP-Q 
(MF066646), allowing the identification of complementary regions in draft genomes using 
Mauve302. Coordinates were recorded for the pathogenicity island region from the contigs of each 
genome which were then manually extracted. The sequences from each VPaI were then aligned 
by MAFFT303. The aligned sequences file was then analyzed and an ML tree constructed as 
described for tdh genes. Subsequently, phylogeny and recombination among islands from select 
genomes was also conducted using the aligned FASTA file in Gubbins68 with the default setting. 
The identities of genes within recombining regions were determined based on the coordinates of 
the reference sequence. To determine the phylogeny of effector orthologs, all ortholog gene 
sequences were extracted from both draft and closed genomes using BLASTn254. Orthologs 
identified using BLASTx254 with 99% sequence identity and ranging from 61.28% -98.49% query 
coverage were used as outgroups. Alignments were performed by MAFFT303 and maximum-
likelihood (ML) tree was constructed using RAxML 304. Phylogenetic trees were viewed and color-
coded in Interactive Tree Of Life (iTOL) 305.  Alignments were viewed in MEGA269 to visualize 
amino acid variability. Gene content and order of the VPaI elements in MAVP-Q and CT4291 
were illustrated by Easyfig 306.  
 
Molecular genetic methodologies and plasmid construction 
PCR SOE and cloning 
Primers for generating constructs used in marker exchange mutagenesis were designed as 
recommended 255. Oligonucleotide primers were synthesized by © Integrated DNA Technologies 
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(Coralville, IA). PCR cycling conditions were optimized using AccuStart II PCR SuperMix 
(Quantabio, Beverly, MA). Genomic DNA from V. parahaemolyticus strain MAVP-Q, a ST631 
clade II member containing VPaIγ, from VPaIγ,  and  strain MAVP-C, a pandemic ST3 strain 
containing VPaIα,was used as a template to generate amplicons upstream and downstream of the 
gene of interest, whereas amplicons of the antibiotic cassettes were generated using plasmids 
pBD4 and pEVS170 (Table 2.4). Genomic DNA was prepared by organic DNA extraction 256. 
Oligonucleotide primers for gene knockouts were designed to contain at least 400bp regions 
flanking the gene of interest to enable efficient recombination (Table 2.3). Oligonucleotide primers 
for the antibiotic cassette to replace the gene of interest were designed to contain the native 
antibiotic resistance cassette promoter from the plasmid (Table 2.3). Analysis of the secondary 
structure of primers was performed by NetPrimer (©PREMIER Biosoft). Gene knockouts and 
antibiotic resistance genes were amplified from target DNA with Phusion® High-Fidelity DNA 
Polymerase or Phusion® High-Fidelity PCR Master Mix (©New England Biolabs, Ipswich, MA) 
according to ©New England Biolabs Inc. protocol. PCR SOE was performed as described 255.  
PCR SOE product was cloned into pCR2.1TOPO® and transformed into chemically competent E. 
coli 10-beta cells (New England Biolabs®, Ipswich, MA) following Invitrogen pCR2.1TOPO®  
(Invitrogen K202020) protocol. Plasmid DNA was purified using ©QIAGEN Plasmid Kit protocol 
with house-made ©QIAGEN reagents. Confirmation that the constructs contained no PCR 
generated errors was determined by sequencing using the Sanger method by ©GENEWIZ LLC 
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Transformation of V. parahaemolyticus 
V. parahaemolyticus strains harboring pSEE1 were grown to turbidity in LBS and subsequently a 
2% inoculum was used to grow an overnight culture at RT in minimal medium supplemented with 
0.2% arabinose. Once cultures reached OD600 > 0.5, 0.5 mL culture was mixed with 2 µg of either 
plasmid DNA or ~10 µg of genomic DNA that was sheared by freeze-thaw three times at -20°C, 
and incubated at 28°C statically for 30 minutes. 0.5 mL LBS was added to the culture and was 
incubated at 37°C for 20-60 minutes. Cells were pelleted and suspended in ~50 µl LBS broth. 
Equal volumes of transformant were plated onto three concentrations of antibiotic flanking 
estimated optimal concentration (10/12/15 µg/ml gentamycin and  2.5/5/8 µg/ml erythromycin) 
and grown at 37°C overnight. Colonies were re-streaked to a plate with a higher concentration of 
antibiotic, grown at 37°C, then the colony screened by PCR to identify the presence of the 
mutation. Mutants harboring pSEE1 were passaged at a 2% inoculum in LBS twice per day for 
two days to lose plasmid.  
 
Acanthamoeba castellanii predation assay  
 Overnight cultures of V. parahaemolyticus were grown in LBS + 0.04% bile salts was subcultured 
1% into fresh LBS + 0.04% bile salts and grown at 37°C until OD600 = ~0.5-1.0. Cultures were 
washed once in PBS and adjusted to an OD600 = 0.125. Eight 10-fold dilutions of culture were 
performed in 96 well plate. Six-day old A. castellanii culture was pelleted at 500g for 4 minutes 
and resuspended in PBS. A. castellanii were adjusted to 1x105 cells/mL, and an equal volume of 
A. castellanii was gently mixed with the V. parahaemolyticus dilutions. After 4 minutes of co-
culture, 10µL dilutions of each well were spotted onto an LB agar plate and grown at room 
temperature for two days.  
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Galleria mellonella 
Overnight cultures of V. parahaemolyticus were subcultured 1% into fresh LBS + 0.04% bile salts 
to induce T3SS activity, or with no addition, and grown to mid-log phase. Pelleted cells were 
washed with Phosphate’s Buffered Saline (PBS) twice, and the OD600 used to estimate cell 
numbers taken and cells diluted appropriately.  G. mellonella were separated into treatment groups 
and two controls: one no-injection and one injected with PBS. All individuals in the treatment 
groups were inoculated with 10ul diluted V. parahaemolyticus in PBS, and their survival and 
health were monitored and recorded at 24 hours, 48 hours and 72 hours post-inoculation. The 
Colony Forming Units (CFU) were determined by the direct plating method for each inoculum 
dose. G. mellonella were scored for survival, activity, cocoon formation and melanization and a 
health index score was calculated for each treatment as per Tsai 2016 277. 
 
Toxin expression vector construction  
To express putative toxins in yeast, genes were cloned from designated V. parahaemolyticus 
strains, cloned into a pYES2.1/V5-His-TOPO® (Invitrogen) vector shuttle plasmid that can be 
generated in E. coli, and then expressed in yeast. The forward oligonucleotide primers to amplify 
toxins contained a synthetic altered Kozak sequence (FRBS) overlapping the start codon of the 
gene of interest as recommended by manufacturer (Invitrogen). The forward primer contained the 
native sequence, except for the bolded nucleotides surrounding the underlined start codon 
(G/A)NNATGG for optimal expression in yeast. The reverse primer was designed for 
amplification near or at the stop codon of the gene of interest. Both primers were designed with a 
melting temperature between 63°- 67°C, and within 1°C of each other. Melting temperatures and 
  105 
the secondary structure was analyzed by NetPrimer (©PREMIER Biosoft). Oligonucleotide 
primers were synthesized by ©Integrated DNA Technologies (Coralville, IA). PCR cycling 
conditions were optimized using AccuStart II PCR SuperMix (Quantabio, Beverly, MA). Toxin 
genes were amplified with Phusion® High-Fidelity DNA Polymerase or Phusion® High-Fidelity 
PCR Master Mix (©New England Biolabs, Ipswich, MA) according to ©New England Biolabs 
Inc. protocol. PCR products were cloned into a pYES2.1/V5-His-TOPO vector (See Table 2.4) 
and transformed into One-Shot TOP10F’ E. coli ® following pYES2.1 TOPO™ TA Yeast 
Expression Kit (Invitrogen) protocol. Plasmid DNA was prepared using ©QIAGEN Plasmid Kit 
protocol with house-made ©QIAGEN reagents and absence of errors confirmed by sequencing 
and analysis ©GENEWIZ LLC (South Plainfield, NJ, USA).  
 
Yeast Transformation 
To generate competent S. cerevisiae, five colonies of S. cerevisiae BY4742 were grown overnight 
with shaking at 28°C. Cultures were diluted to an OD600 of 0.4 in 25 ml of YPD medium and 
grown an additional three hours at 28° while shaking. S. cerevisiae was washed twice in 1X 
LiAc/0.5X TE for a final volume of 1 mL. S. cerevisiae was incubated for 10 minutes at room 
temp. 50µL of S. cerevisiae cells were incubated with 10µL of sheared salmon sperm DNA and 
1µg of plasmid prep of toxin:pYES2.1/V5-His-TOPO® for 1hr at 30°C. The sample was mixed 
with 250µL 40% PEG 3350 and incubated at 30°C for at least 1hr. Samples were heat-shocked for 
15min at 42°C, pelleted, and resuspended in 80µL Milli-Q water. Samples were plated on SC-MM 
medium containing 2% glucose and incubated for two days at 28°C/30°C. 
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Assessment of effector toxicity by heterologous expression in yeast 
To assess the effect of each putative toxin on yeast, S. cerevisiae harboring pYES2.1/V5-His-
TOPO® containing individual toxins were streaked for isolation onto SC-MM + glucose 2% and 
grown for two days at 28°C. Since glucose can mildly repress the GAL1 promoter driving each 
toxin gene, individual colonies were streaked onto SC-MM + raffinose 2% and grown for two days 
at 28°C. S. cerevisiae grown in raffinose was inoculated into SC-MM + raffinose 2% broth and 
grown overnight at 28°C with shaking. Overnight cultures were washed in Milli-Q water, adjusted 
to an OD600 of 2.0, and diluted serially four-fold. 10µL of each dilution was spotted onto SC-MM 
+ glucose 2% agar plates to assess normal yeast growth and SC-MM + galactose 1%/raffinose 1% 
agar plates to assess yeast growth when galactose induces production of each putative toxin and 
grown for two days at 28°C.  
 
Yeast Enumeration 
To calculate the effect of each toxin on the yeast, CFU/mL was estimated for S. cerevisiae growth 
on SC-MM +glucose 2% agar plates (inducing conditions) and SC-MM + galactose 1%/raffinose 
1% agar plates (non-inducing conditions). After two days, log reduction in growth was calculated 
by the following formula: Log Reduction = log10(CFU/mL S. cerevisiae from SC-MM +glucose 
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Cytotoxicity Assay 
Eukaryotic cell culture 
Caco-2 cells were regularly maintained in Dulbecco’s modified Eagle’s medium (DMEM, 
ATCC®) containing 10% (v/v) Fetal Bovine Serum (FBS, Sigma®) and Corning® Antibiotic-
Antimycotic Solution at 37°C in 5% CO2.  
 
Cytotoxicity measurements 
Caco-2 cells at 80% confluency were washed in DMEM without phenol red + 10% FBS and seeded 
25µL of cells at 315 cells/µl in 384-well plates and cultured for 48hr at 37°C in 5% CO2 to 
confluency. Unmodified V. parahaemolyticus strains were streaked for isolation onto LBS agar, 
ΔvscN1:Gen V. parahaemolyticus mutants were streaked for isolation onto LBS + 5 µg/ml Gen, 
and ΔvscN1:Gen/Δ(gene of interest):Erm V. parahaemolyticus mutants were streaked for isolation 
onto LBS + 5 µg/ml Erm. All V. parahaemolyticus strains were grown at 37°C until robust colony 
growth. Five colonies of V. parahaemolyticus were grown overnight in LBS + 0.04% bile salts at 
37°C in a roller drum. Cultures were washed twice in PBS and diluted to add 5µL of culture to 
48hr Caco-2 cells at an MOI of 10. Three replicates per sample were added to Caco-2 cells. After 
6hrs of co-culture, the release of lactate dehydrogenase (LDH) into the medium was quantified by 
using a CytoTox96® non-radioactive cytotoxicity kit (Promega®) according to the manufacturer’s 
instructions. To quantify percent cytotoxicity, the LDH release was calculated with the following 
equation: [optical density at 490 nm (OD490) of experimental release - OD490 of spontaneous 
release]/(OD490 of maximum release - OD490 of spontaneous release)*100%. Spontaneous release 
is the amount of LDH released from the cytoplasm of uninfected cells, whereas the maximum 
release is the total amount of LDH released after the complete lysis of uninfected cells. 
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Statistical Analysis 
For G. mellonella killing assay health index score was calculated for each treatment as per Tsai 
2016 277, and Student’s t pairwise comparisons performed for each pair. For yeast, CFU/mL was 
estimated from colony growth under non-inducing and inducing conditions.  Reduction in growth 
upon induction was compared across samples with Tukey Kramer HSD in pairwise comparisons. 
Data from Caco-2 cytotoxicity assay represents the mean ± standard deviation from one 
experiment using five individual bacterial colonies per strain, performed in triplicate. Pairwise 
comparison across strains was performed utilizing Tukey Kramer HSD. 
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Table 3.3 Strains and plasmids used in this study 
Strain or plasmid Description Source of Reference 
E. coli strains     
  One-Shot TOP10F’ 
 Thermo Fisher® 
  10-beta cells  New England Biolabs® 
        
V. parahaemolyticus strains   
  MAVP-Q WT GCA_002209725.2 
  TBD MAVP-Q derivative ΔvscN1:Gen This study 
  TBD MAVP-Q derivative ΔvscN1:Gen ΔvscN2:Erm This study 
  TBD MAVP-Q derivative ΔvscN1:Gen ΔORF32:Erm This study 
  TBD MAVP-Q derivative ΔvscN1:Gen ΔORF34_ORF35:Erm This study 
  TBD MAVP-Q derivative ΔvscN1:Gen ΔORF85:Erm This study 
  TBD MAVP-Q derivative ΔvscN1:Gen ΔORF90:Erm This study 
  TBD MAVP-Q derivative ΔvscN1:Gen ΔvopV:Erm This study 
  TBD MAVP-Q derivative ΔvscN1:Gen ΔvopZ:Erm This study 
  CT4287 WT This study 
  TBD CT4287 derivative ΔvscN1:Gen This study 
  TBD CT4287 derivative ΔvscN1:Gen ΔvscN2:Erm This study 
  TBD CT4287 derivative ΔvscN1:Gen ΔORF32:Erm This study 
  TBD CT4287 derivative ΔvscN1:Gen ΔORF34_ORF35:Erm This study 
  TBD CT4287 derivative ΔvscN1:Gen ΔORF85:Erm This study 
  TBD CT4287 derivative ΔvscN1:Gen ΔORF90:Erm This study 
  TBD CT4287 derivative ΔvscN1:Gen ΔvopV:Erm This study 
  TBD CT4287 derivative ΔvscN1:Gen ΔvopZ:Erm This study 
        
S. cerevisiae strains   
  BY4742 his3-Δ1 leu2-Δ0 ura3-Δ0 lys2-V0 Pearce 1999 
        
A. castellanii     
  30234™    ATCC® 
        
G. mellonella     
  N/A N/A Grubco 
      
Plasmids     
  pSEE1  Competency plasmid; ChlR This Study 
  pBD4 Gm
R cassette, ErmR Duerkop 2007 
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  pEVS170 
ErmR cassette, ChlR, mini-Tn5-Erm, oriVR6K oriTRP4 
KanR Adin 2008 
  pCR2.1-TOPO cloning vector, Kan
R Thermo Fisher Scientific 
  pSEE21 
pCR2.1-TOPO:ST674ORF32::Erm   ST674 ORF32 
knockout, ChlR, ErmR This Study 
  pSEE22 
pCR2.1-TOPO:ST674ORF34.5::Erm   ST674 
ORF34/ORF35 knockout, ChlR, ErmR This Study 
  pSEE23 
pCR2.1-TOPO:ST674ORF76::Erm   ST674 ORF76 
knockout, ChlR, ErmR This Study 
  pSEE24 
pCR2.1-TOPO:ST674ORF81::Erm   ST674 ORF81 
knockout, ChlR, ErmR This Study 
  pSEE25 
pCR2.1-TOPO:ST674ORFVopV::Erm   ST674 VopV 
knockout, ChlR, ErmR This Study 
  pSEE26 
pCR2.1-TOPO:ST674ORFVopZ::Erm   ST674 VopZ 
knockout, ChlR, ErmR This Study 
  pSEE27 pYES2.1-V5-His-TOPO::ST631ORF32 This study 
  pSEE28 pYES2.1-V5-His-TOPO::ST631ORF34 This study 
  pSEE29 pYES2.1-V5-His-TOPO::ST631ORF35 This study 
  pSEE30 pYES2.1-V5-His-TOPO::ST631ORF76 This study 
  pSEE31 pYES2.1-V5-His-TOPO::ST631ORF81 This study 
  pSEE32 pYES2.1-V5-His-TOPO::ST631VopA This study 
  pSEE33 pYES2.1-V5-His-TOPO::ST631VopC This study 
  pSEE34 pYES2.1-V5-His-TOPO::ST674ORF32 This study 
  pSEE35 pYES2.1-V5-His-TOPO::ST674ORF34 This study 
  pSEE36 pYES2.1-V5-His-TOPO::ST674ORF35 This study 
  pSEE37 pYES2.1-V5-His-TOPO::ST674ORF76 This study 
  pSEE38 pYES2.1-V5-His-TOPO::ST674ORF81 This study 




Table 3.4: Oligonucleotides used in this study. 
Primer name Target Gene DNA 
template 
Sequence 
Genetic Knockouts       
  PrSEE70 674_vscN2_Erm AF vscN2 CT4291 
gDNA 
TGAAATTGGCAAAGCG 
  PrSEE71 vscN2_Erm AR vscN2 CT4291 
gDNA 
GTTTCCGCCATTCTTTGGTGTCTTGATATGACTCCTT 
  PrSEE72 vscN2_Erm BF ErmR 
cassette 
pEVS170 AAGGAGTCATATCAAGACACCAAAGAATGGCGGAAAC 
  PrSEE73 vscN2_Erm BR ErmR 
cassette 
pEVS170 AGACAGCCGAACGTACTCCTTTACAAAAGCGACTCATAGA 
  PrSEE74 vscN2_Erm CF vscN2 CT4291 
gDNA 
TCTATGAGTCGCTTTTGTAAAGGAGTACGTTCGGCTGTCT 
  PrSEE75 vscN2_Erm CR vscN2 CT4291 
gDNA 
TGATACCCAGTCATAATAAATG 
  PrSEE76 32_Erm AF ORF32 CT4291 
gDNA 
AGGTATTACTCAAGAAGGACTGT 
  PrSEE82 674 32_Erm AR ORF32 CT4291 
gDNA 
GTTTCCGCCATTCTTTGAGTGTTAGTTATGTTATGTTGTTT 
  PrSEE83 674 32_Erm BF ErmR 
cassette 
pEVS170 AAACAACATAACATAACTAACACTCAAAGAATGGCGGAAAC 




  PrSEE85 674 32_Erm CF ORF32 CT4291 
gDNA 
TCTATGAGTCGCTTTTGTAAATATCAACGATTAGTATTTGTTCT 
  PrSEE86 674 32_Erm CR ORF32 CT4291 
gDNA 
TAGCGGTAGACACCAGCA 
  ORF34.5SoAF ORF34-35 CT4291 
gDNA 
ATAACAACGGTTGATTTAATACTCTT 
  ORF34.5SoAR ORF34-35 CT4291 
gDNA 
GTTTCCGCCATTCTTTGCTAACTCTGTTGAATGTAGG 
  ORF34.5SoBF ErmR 
cassette 
pEVS170 CCTACATTCAACAGAGTTAGCAAAGAATGGCGGAAAC 
  ORF34.5SoBR ErmR 
cassette 
pEVS170 GTTCTAACCATAGGACTGATTTACAAAAGCGACTCATAGA 
  ORF34.5SoCF ORF34-35 CT4291 
gDNA 
TCTATGAGTCGCTTTTGTAAATCAGTCCTATGGTTAGAAC 




  PrSEE63 674 85 SoAF ORF76 CT4291 
gDNA 
AAGGGCGTTATTGGAGG 
  PrSEE64 674 85 SoAR ORF76 CT4291 
gDNA 
CGTTTCCGCCATTCTTTAATGATTTCCATACAGTTAGAGTC 
  PrSEE65 674 85 SoBF ErmR 
cassette 
pEVS170 GACTCTAACTGTATGGAAATCATTAAAGAATGGCGGAAACG 
  PrSEE66 674 85 SoBR ErmR 
cassette 
pEVS170 TTTCTCGTCTGACTCAACTTTACAAAAGCGACTCATAGA 
  PrSEE67 674 85 SoCF ORF76 CT4291 
gDNA 
TCTATGAGTCGCTTTTGTAAAGTTGAGTCAGACGAGAAA 
  PrSEE68 674 85 SoCR ORF76 CT4291 
gDNA 
TCACCATAGCTGCGTTG 
  PrSEE55 674 90SoAF ORF81 CT4291 
gDNA 
ATAGGCAGTTGAATGTTAAGTT 
  PrSEE56 674 90SoAR ORF81 CT4291 
gDNA 
GTTTCCGCCATTCTTTGTATTAACATTTTTACCCA 
  PrSEE57 674 90SoBF ErmR 
cassette 
pEVS170 TGGGTAAAAATGTTAATACAAAGAATGGCGGAAAC 
  G88SoBR ErmR 
cassette 
pEVS170 GGATGTATTTCGGGTTGTTTACAAAAGCGACTCATAGA 
  G88SoCF ORF81 CT4291 
gDNA 
TCTATGAGTCGCTTTTGTAAACAACCCGAAATACATCC 
  G88SoCR2 ORF81 CT4291 
gDNA 
GTTATTGACACTGATAGTGGCTT 
          
Yeast Toxicity Assay       
  674_32YES FRBS ORF32 CT4291 
gDNA 
AAAATGCCTATATCTTTAACCGGATGTTT 
  674_32YES R ORF32 CT4291 
gDNA 
TCAGTCCACTTCTGAATACAGTGTTTCTCTG 
  PrSEE52 34YES FRBS2 631_674 ORF34 CT4291 
gDNA 
TTGATGGTTTGTTTTTCAGGTTTTTTC 
  PrSEE53 34YES R2 631_674 ORF34 CT4291 
gDNA 
TACAACTAGTCTCCAGCCTAATGTACCGT 
  35YES F ORF35 CT4291 
gDNA 
GAAATGAGTATTATGATTCCTACATTCAACAGAG 
  35YES R ORF35 CT4291 
gDNA 
CTAAAATCAAATCCTTTCTATCAATGTTCACT 




  674_85YES R ORF76 CT4291 
gDNA 
CAGAAAATCTCTGCTAATGTAAAATTAACC 
  674_90YES FRBS ORF81 CT4291 
gDNA 
AAAATGGTAATACAAAGCCAAAAACTGAGA 
  674_90YES R ORF81 CT4291 
gDNA 
TTACCATATAATACCATGTTCACGAAGTATA 






CHAPTER IV: CONCLUSION 
This study identified four effectors unique to VPaIß/γ and absent from the pandemic 
VPaIα, and suggests that three alleles could contribute to the clinical success of tdh3-VPaIγ. The 
most useful tool generated from this work is the construction of pSEElostfoX and the 
corresponding rapid Vibrio natural transformation protocol. When in the presence of arabinose, 
pSEElostfoX induces natural competence in V. parahaemolyticus and V. fischeri. This allows for 
rapid transformation and genetic deletions in these species. This tool is to rapidly generate 
mutations can hopefully be utilized in other Vibrio labs. 
This work provides a series of eukaryotic models that can be used to evaluate the role of 
T3SS effectors in V. parahaemolyticus. The S. cerevisiae toxicity model optimized in this study 
can easily be utilized for other toxin identification for other bacteria and initial assessment due to 
its ease of use, and rapid results. As exemplified by expression of the known effector VopZ, this 
model does have limitations of evaluating toxins that elicit a singular cell effect. After multiple lab 
members had trouble reproducing data from previous work 273, the A. castellanii co-culture model 
optimized in this study can be used to evaluate individual effectors. G. mellonella is a popular 
model to study bacterial virulence in the presence of an innate immune system such as pathogens 
would experience during human infection. This model was developed for our V. parahaemolyticus 
collection by Kara Rzasa as an undergraduate research project, before her graduation. We expect 
to achieve a higher resolution of this model with further experiments and perhaps knockout of 
hemolysin genes tdh and trh. The final eukaryotic model developed in this study was the use of 
Caco-2 cells to assess the cytotoxic effect of T3SS toxins on human colon cells. Other Whistler 





follow the progression through these eukaryotic models for their V. parahaemolyticus work, or 
quickly adapt these to other bacteria as has already been done for V. fischeri work in the Whistler 
lab.  
Further characterization of the effectors is warranted to understand their contribution 
towards infection and environmental persistence. The first step will be to assess if each of the 
effectors is secreted by the T3SS 166. A secretion assay will also assess if differences in cytotoxicity 
between tdh3-VPaIγ and tdh5-VPaIγ are related to differences in secretion rates of the effectors. 
Scanning Electron Microscopy images of V. parahaemolyticus-induced effacement of the 
enterocyte brush border with Caco-2BBe cells will visualize the V. parahaemolyticus infection 
and evaluate if an effector contributes to the infection process. Further characterization of the 
mucin-degradation potential of ORF34 is warranted. Co-culture with a mucus-producing cell line 
such as HT29-MTX followed by an enzyme-linked immunosorbent assay (ELISA) could be used 
to characterize this protein further. Finally, the use of the premier model for gastric infection, the 
infant rabbit infection model, can truly assess whether the effectors play a role in gastric disease. 
A better representation of environmental fitness would be the use of microcosms. Microcosms 
with natural seawater would provide a more appropriate setting for assessment of V. 
parahaemolyticus environmental fitness than the controlled settings in the A. castellanii model.  
The blocks of homoplasy in the VPaIs (Figure 3.3) indicates that these islands are evolving 
in geographic populations. Now present in the North Atlantic, it is likely that these four lineages 
of VPaI will continue this geographic population evolution and begin to recombine with each 
other. This work is important because if we can better understand the effector(s) that influence 





tdh3-, tdh5-, tdh6-, or  tdh7-VPaIγ, but as these islands evolve if they contain the effector allele 
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